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CHAPTER 1 
INTRODUCTION 
 
Inflammatory Breast Cancer.  Inflammatory breast cancer (IBC) is the 
most lethal type of breast cancer with a three-year survival rate of 42% as 
compared to 85% for non-IBC (Chang et al., 1998b).  The incidence of IBC is 
relatively low but varies depending on geographic region.  For example, an 
analysis by Hance et. al reported that IBC accounts for approximately 2.5% of all 
breast cancer cases in the USA (Hance et al., 2005) whereas in parts of northern 
Africa rates may be as high as 10% (Boussen et al., 2010).  The unique clinical 
presentation and symptoms of primary IBC, described below, are quite distinct 
from non-IBC (Walshe and Swain, 2005) and because it is rare, clinicians are 
less familiar with the disease.  Upon physical examination, a palpable discrete 
mass is absent in many patients and IBC is often misdiagnosed as mastitis, a 
benign bacterial infection.  Therefore, accurate and early diagnosis is critical due 
to the aggressiveness and rapid onset of IBC.  In 2010, an international panel of 
leading experts recommended that the clinical consensus for a minimal standard 
diagnosis of IBC include erythema occupying at least one-third of the breast, 
hardening and retraction of the nipple, dimpling (peau d’orange) of the skin 
caused by enlarged hair-follicle pits that does not respond to antibiotic treatment 
(Dawood et al., 2010) (Figure 1.1).  More than half to 85% of patients present 
with axillary or supraclavicular lymph node metastases
	  	  
2 
 
         
Figure 1.1.  Clinical signs of IBC and variations in presentation.  (A) Primary              
IBC with synchronous bilateral erythema with minimal breast edema.  (B) An 
African American IBC patient with increased breast size and peau d’orange with 
minimal erythema.  (Robertson et al., 2010) 
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 (Walshe and Swain, 2005).  Indeed, classification of IBC is considered at least 
Stage IIIB or higher depending on nodal status and the presence of distant 
metastases (Edge et al., 2010). 
Mammographic and ultrasonographic imaging are both important for IBC 
diagnosis and disease assessment and often reveal the absence of an 
underlying discrete mass or lump.  Ultrasonographic evaluation has proved 
significant for detection of skin, pectoral muscle and axillary lymph node 
involvement and also for revealing masses.  Masses may be otherwise masked 
by accompanying inflammatory changes such as skin thickening and stromal 
coarsening and/or increased density when evaluated by mammography 
(Gunhan-Bilgen et al., 2002).  The clinical manifestation and characteristic 
imaging profile of the involved breast are thought to reflect dermal lymphatic 
invasion, in which invasive cellular aggregates or tumor emboli in dermal 
lymphatics block drainage of these vessels. 
 IBC is an aggressive and fatal invasive breast cancer and therefore 
studies have focused on establishing epidemiological risk factors, identifying 
molecular features and defining the specific biology of IBC.  Risk factors highly 
associated with IBC include younger age at diagnosis, high body mass index and 
African American ethnicity (Chang et al., 1998a; Levine and Veneroso, 2008).  
Over-expression of the Ras superfamily member RhoC and loss of WISP3 may 
be two key and related events in the development of IBC (Miao et al., 2003).  IBC 
tumors, in comparison to non-IBC tumors, have a higher occurrence of p53 gene 
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mutations (Riou et al., 1993; Gonzalez-Angulo et al., 2004), increased 
expression of angiogenic and lymphangiogenic factors including VEGF, IL-6, IL-8 
and VEGF receptor 3 (Van der Auwera et al., 2004), and a greater incidence of 
HER2 positivity and EGF receptor (Guerin et al., 1989; Parton et al., 2004).  In 
IBC, high levels of the cysteine protease cathepsin B correlate with increases in 
numbers of metastatic lymph nodes (Nouh et al., 2011).  Caveolin-1, which was 
initially hypothesized to be a tumor suppressor in breast cancer (Bouras et al., 
2004), is highly expressed in both IBC cells and tissues (Van Laere et al., 2005; 
Van den Eynden et al., 2006; Nouh et al., 2011).  Recent data suggest that high 
expression of caveolin-1 is a characteristic of triple-negative and other basal-like 
breast cancers (Elsheikh et al., 2008), including IBC of a basal phenotype.   
 
Caveolin-1 and Caveolae.  Caveolin-1, a 22-kDa protein, was first 
identified in Rous sarcoma virus transfected fibroblasts as a phosphorylation 
substrate of v-Src (Glenney, 1989).  Caveolin-1 belongs to a family of three 
highly conserved proteins.  Caveolin-1 and caveolin-2 are expressed in most 
tissues and caveolin-3 is muscle specific.  The caveolins have a hairpin loop 
structure that is inserted into the inner leaflet of the plasma membrane with the 
N- and C-termini exposed to the cytoplasm (Glenney and Soppet, 1992).  
Cholesterol binds caveolin-1 via a putative cholesterol-binding domain and this 
interaction is thought to facilitate its oligomerization (Murata et al., 1995).  
Assembly of caveolin-1 oligomers at the plasma membrane forms the structure 
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and scaffold of caveolae (Monier et al., 1995; Fernandez et al., 2002) with the 
integrity and function of caveolae dependent on membrane cholesterol (Rothberg 
et al., 1992).  First identified in the 1950s by electron microscopy, caveolae are 
omega-shaped plasmalemmal invaginations approximately 50-100 nm in 
diameter.  Caveolae are specialized cholesterol- and sphingolipid-rich 
microdomains that are distinct from other lipid rafts as well as from the general 
plasma membrane and clathrin-coated vesicles (Schnitzer et al., 1995b; 
Anderson and Jacobson, 2002).  The lipid raft model originated from 
observations that glycosphingolipids first cluster in the Golgi apparatus before 
being sorted to the apical surface of epithelial cells (Simons and van Meer, 
1988).  Subsequent studies demonstrated that sphingolipid-cholesterol rafts 
(including caveolae) are insoluble in the detergent Triton X-100 at 4°C, resulting 
in detergent–insoluble or –resistant membranes.  As a result of the elevated lipid 
content, these detergent-insoluble membranes float to a light buoyant density on 
sucrose gradients (Brown, 1994) along with associated proteins.  This has led to 
purification techniques and use of cholesterol-modulating agents for the study of 
lipid rafts and caveolae (Sargiacomo et al., 1993; Smart et al., 1995; Song et al., 
1996).  In prostate cancer models, strategies to disrupt cholesterol-rich structures 
have elucidated their associated proteins and functions in tumor progression [for 
review see (Di Vizio et al., 2008)].  For example, targeted disruption of lipid rafts 
with cholesterol binding agents inhibits EGF receptor and Akt1 phosphorylation 
and reduced survival of prostate cancer cells (Zhuang et al., 2002; Oh et al., 
	  	  
6 
2007).  Alternatively inhibiting cholesterol biosynthesis alters lipid raft 
composition, i.e. decreased cholesterol content and phosphorylated Akt, inhibits 
Akt pathway signaling and induces apoptosis in prostate cancer cells and 
xenografts (Zhuang et al., 2005).  Recently, quantitative proteomics is being used 
to map the lipid raft proteome, studies which may identify tumor biomarkers and 
therapeutic targets (Staubach and Hanisch, 2011). 
   
Specific Functions of Caveolae and Caveolin-1.  Caveolae play 
functional roles in both endocytosis and transcytosis (Montesano et al., 1982; 
Schnitzer et al., 1994; Schnitzer et al., 1995a; Schnitzer, 2001).  Caveolae 
associated signaling molecules have also been identified: a number of 
heterotrimeric G proteins (Oh and Schnitzer, 2001), non-receptor tyrosine 
kinases (Liu et al., 1997) and Ras (Rizzo et al., 1998).  Thus, caveolae 
compartmentalize signaling pathways and may act as cell surface structures for 
regulated signal transduction.  Caveolin-1 protein directly interacts with many of 
the aforementioned as well as several other proteins and lipids, e.g. insulin 
receptor and GM1  [for review see (Liu et al., 2002a)] indicating its role in lipid 
transport, lipid trafficking and signal transduction.  We propose that caveolae also 
serve as sites on the cell surface linking signaling pathways and proteolytic 
networks that are involved in tumor invasion.   
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Proteases and Their Receptors in Caveolae.  We previously 
hypothesized that the high levels of caveolin-1 expression in bladder, colon, 
esophageal and prostate cancers promote cell surface proteolytic events that 
lead to extracellular matrix (ECM) degradation and tumor invasion [for review see 
(Cavallo-Medved and Sloane, 2003)].  Annexin II, a member of a family of 
membrane-binding proteins that bind to negatively charged phospholipids in a 
calcium-dependent manner [for review see (Gerke and Moss, 2002), localizes to 
caveolae in many cell types (Sargiacomo et al., 1993; Lisanti et al., 1994; 
Cavallo-Medved et al., 2005).  Annexin II (or p36), like caveolin-1, is a v-Src 
substrate (Soric and Gordon, 1986) and exists both as a monomer and in a 
heterotetrameric complex, referred to as the annexin II heterotetramer (AIIt).  AIIt 
consists of two subunits of annexin II, the heavy chain, bound to a homodimer of 
S100A10 (also called p11), the light chain.  The amino terminus of annexin II 
contains the binding site for its hydrophobic interactions with S100A10 (Rety et 
al., 1999).  The heavy chain, annexin II, is a collagen I binding protein (Santoro et 
al., 1994).  Chung et al. found that the annexin II tetramer interacts with an 
alternatively spliced segment of tenascin C on the cell surface of U-251MG 
human glioma cells (Chung and Erickson, 1994).  Usually absent from most adult 
tissues, tenascin C reappears in places of active tissue regeneration and cell 
migration, i.e., in tumors and areas of wound healing (Mackie et al., 1988; 
Koukoulis et al., 1991).  The AIIt is a receptor for and regulatory complex of 
plasminogen (MacLeod et al., 2003).  Our laboratory demonstrated that the AIIt 
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serves as a binding platform for cathepsin B on the surface of tumor cells (Mai et 
al., 2000).  More specifically, we have shown that in colon cancer cells cathepsin 
B and AIIt localize in caveolae (Cavallo-Medved et al., 2003). Proteases of the 
plasminogen cascade, specifically pro-urokinase plasminogen activator (pro-
uPA) and its receptor uPAR have also been localized to caveolae (Stahl and 
Mueller, 1995; Cavallo-Medved et al., 2005).  These findings may be of functional 
significance as cathepsin B is capable of processing the zymogen pro-uPA to its 
active derivative uPA (Kobayashi et al., 1991), which in turn can activate 
plasminogen bound to AIIt.  A proteolytic pathway involving cathepsin B and uPA 
has been identified upstream of plasminogen on the surface of a number of cell 
lines (Kobayashi et al., 1992; Kobayashi et al., 1993; Guo et al., 2002).  
Moreover, uPAR complexes with caveolin-1 via β1-integrin, an association that 
has been shown to mediate uPAR-dependent adhesion and β1-integrin-induced 
signal transduction (Wei et al., 1999; Schwab et al., 2001).  Localization of these 
enzymes and their receptors to caveolae supports the hypothesis that proteolytic 
cascades may be initiated in caveolae and participate in tumor invasion via the 
degradation of extracellular matrix components (Figure 1.2). 
 
Cathepsin B: Intracellular Trafficking and Activity.  Cathepsin B is a 
ubiquitously expressed lysosomal cysteine protease of the papain family.  In the 
acidic lysosomal environment, cathepsin B functions in protein degradation in 
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Figure 1.2. Proteases localize to caveolae at the surface of tumor cells. 
Caveolae are distinct lipid microdomains that are small invaginations of the 
plasma membrane formed by the oligomerization of the structural protein 
caveolin-1.  Cathepsin B, uPA and their respective receptors, the annexin II 
heterotetramer and uPAR, localize at the tumor cell surface in caveolae.  The 
bidirectional interaction between cathepsin B and uPA is one example of a 
proteolytic network clustering in caveolae that may affect tumor progression. 
 Arrows indicate cleavage events that activate pro-enzymes.  Adapted from 
(Rothberg et al., 2011). 
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mammalian cells, exhibiting broad substrate specificity (Mort and Buttle, 1997).  
Some redundancy in function of cysteine cathepsins might explain why the 
absence of cathepsin B is not lethal.  Analyses of knockout mice have 
demonstrated significant roles for cathepsin B in trypsinogen activation in 
pancreatitis and also TNF-alpha specific.  Non-redundant functions of cathepsin 
B suggest its involvement in processes of physiology and pathology (Guicciardi 
et al., 2000; Halangk et al., 2000). 
 The single human cathepsin B gene is located on chromosome 8p22 
(Fong et al., 1986; Fong et al., 1992).  Cathepsin B mRNA is translated as a 
preprocathepsin B on the rough endoplasmic reticulum.  The signal recognition 
prepeptide directs translated mRNA into the rough endoplasmic reticulum.  Two 
N-glycosylation sites, one within the 62 residue proregion and another present in 
the heavy chain, are co-translationally glycosylated.  Following cleavage of the 
17 residue prepeptide, the inactive proenzyme moves through the ER and is 
shuttled into the Golgi apparatus.  Normal trafficking of cathepsin B to the 
lysosome follows the traditional mannose-6-phosphate pathway characteristic of 
lysosomal enzymes.  Therefore, after entry into the Golgi complex, further 
modification of cathepsin B carbohydrate moieties to phosphorylated mannose 
residues enables recognition by membrane bound mannose-6-phosphate 
receptors (MPR).  In the trans-Golgi, the 300-kDa cation-independent CI-MPR 
and the 46-kDa cation-dependent CD-MPR bind the phosphorylated 
carbohydrate moieties of procathepsin B (Ludwig et al., 1993).  Normally 
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procathepsin B is trafficked from the Golgi to the pre-lysosomal compartment of 
late endosomes.  The slightly acidic pH of the late endosomes results in 
dissociation of procathepsin B from MPRs.  Removal of phosphate by acid 
phosphatase from the mannose-6-phosphate residues on cathepsin B prevents 
its retrograde trafficking.  In the late endosome maturation of the enzyme by 
cleavage of the pro-region results in the 31-kDa active cathepsin B species 
(Mach et al., 1992).  Cathepsin B is next transported to perinuclear lysosomes, 
where it normally functions in protein degradation and turnover of cellular 
components. 
Therefore, there are several forms of intracellular cathepsin B.  The 
molecular weight of the inactive species is 43 or 46-kDa, depending upon 
glycosylation.  The active single chain form exists as a 31-kDa protein of 252 
amino acids.  In some tissues, additional proteolytic cleavage of the 31-kDa 
species occurs within the lysosome, the result of which is a double chain form 
composed of a 25/26-kDa heavy chain and 5-kDa light chain, bound by a 
disulfide linkage (Nishimura et al., 1988; Rowan et al., 1992).  The difference in 
heavy chain molecular weight, 25 or 26 kDa, is due to removal of a carbohydrate 
moiety from the latter (Mach et al., 1992).  The active site is within the 5-kDa light 
chain of the double chain form. The double chain cathepsin B is also short two 
amino acids in the heavy chain, a result of their cleavage during processing 
(Figure 1.3). 
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Figure 1.3.  Cartoon illustrating the various cathepsin B species.  Cathepsin 
B mRNA is translated as preprocathepsin B. The signal recognition prepeptide 
directs translated mRNA into the rough endoplasmic reticulum.  The molecular 
weight of the inactive procathepsin B species is 43 or 46-kDa, depending upon 
glycosylation.  Potential glycosylation sites are depicted as “Y”.  The active single 
chain form exists as a 31-kDa protein of 252 amino acids.  In some tissues, 
additional processing of the 31-kDa species by cleavage of a dipeptide occurs 
within the lysosome, the result of which is a double chain form composed of a 
25/26-kDa heavy chain and 5-kDa light chain that are linked by a disulfide bridge.  
Adapted from (Cavallo-Medved and Sloane, 2003). 
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Structurally, cathepsin B is a bilobal protein, containing two globular 
domains, between which the active site and substrate-binding site are located.  In 
its active form, cathepsin B can act either as an endopeptidase, cleaving internal 
peptide bonds, or an exopeptidase, by removing C-terminal dipeptides from a 
substrate (Keppler and Sloane, 1996).  Cathepsin B exhibits this dual peptidase 
activity due to a flexible structural element within the molecule, the occluding 
loop.  At acidic pH, this occluding loop partially blocks the active site of the 
molecule, preventing large protein substrates from entering the active site and as 
a result the enzyme exhibits exopeptidase activity, specifically 
carboxydipeptidase activity.  In a neutral pH environment, the loop is displaced 
and no longer blocks access of proteins to the active site, and therefore 
cathepsin B can act as an endopeptidase cleaving peptide bonds within a 
substrate. 
 
Aberrant Trafficking of Cathepsin B.  In normal cells less than five 
percent of the proenzyme is secreted (Hanewinkel et al., 1987).  Unlike normal 
cells, cancer cells secrete significantly greater amounts of latent pro- and mature 
cathepsin B.  This is observed in human malignancies of the breast (Poole et al., 
1978) and colon (Maciewicz et al., 1989) as well as gliomas (McCormick, 1993).  
The normal location of lysosomes, and therefore cathepsin B, is perinuclear in 
the region of the microtubule organizing center and in the apical pole of polarized 
epithelial cells.  There is altered intracellular distribution of the cathepsin B in 
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tumors, leading to cathepsin B in vesicles throughout the cytoplasm and at the 
cell periphery.  As seen by cathepsin B staining of human colon cancer tissues, 
there is a shift in localization from the apical pole of the cell to the inner basal 
surface of the plasma membrane (Emmert-Buck et al., 1994).  Not only is there a 
change in localization as noted here, but also increased message, protein, and/or 
activity are localized to regions of tumor invasion (Sinha et al., 1993; Emmert-
Buck et al., 1994; Visscher et al., 1994).  
The mechanism for the aberrant intracellular localization of cathepsin B, 
its trafficking to the cell surface and subsequent secretion are yet unknown 
(Figure 1.4).  Experimental data support several hypotheses.  For example, 
studies on macrophages and fibroblasts demonstrated that experimentally 
lowering cytoplasmic pH causes lysosomes to move toward the cell periphery 
(Heuser, 1989).  This movement follows an alteration in microtubules, and does 
not occur if cells are treated with the microtubule depolymerizing agent 
nocodazole.  When evaluating how malignant progression affects the intracellular 
distribution and secretion of cathepsin B, Rozhin et al. incubated malignant cells 
at slightly acidic pH.  Not only did secretion of active cathepsin B increase and 
intracellular levels decrease, but vesicles positive for cathepsin B localized to the 
cell periphery.  These effects were inhibited by treatment with both taxol, a 
microtubule stabilizer, and colchicine, a microtubule poison (Rozhin et al., 1994).  
The studies suggest that modulating pH disrupts the microtubule cytoskeleton 
resulting in the movement and even secretion of lysosomal constituents, i.e.,
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Figure 1.4. Classical and alternative trafficking pathways for cathepsin B. 
This diagram illustrates the potential pathways of cathepsin B trafficking in either 
normal or cancer cells. Normal trafficking of cathepsin B to the lysosome follows 
the traditional mannose-6-phosphate pathway characteristic of lysosomal 
enzymes, indicated by the black arrows. Cathepsin B mRNA is translated as a 
preprocathepsin B on the RER, transported through the Golgi complex, to late 
endosomes and finally to the lysosome.  In tumor cells cathepsin B is still 
trafficked to the lysosome, but is also trafficked by alternative pathways, 
indicated by the red arrows: (1) Procathepsin B is secreted from tumor cells and 
exists as either a soluble or membrane bound form.  (2) Active cathepsin B may 
also be translocated to the plasma membrane via secretory lysosomes that either 
fuse with the plasma membrane or undergo exocytosis and secrete soluble 
cathepsin B.  The blue arrows indicate extracellular cathepsin B.  Adapted from 
(Cavallo-Medved and Sloane, 2003). 
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release of active cathepsin B into the extracellular milieu.  In vitro pH modulation 
may be relevant as it closely imitates the acidic tumor microenvironment found in 
vivo [for reviews, see (Wike-Hooley et al., 1984; Gillies et al., 2002)].  
 To understand cathepsin B functionality through qualitative analysis of 
secretion and membrane association, our lab developed an assay for 
measurement of cathepsin B activity in real time. Pericellular cathepsin B activity 
was shown to be forty to fifty percent membrane associated (Linebaugh et al., 
1999).  Other studies suggest that exocytosis of lysosomes is calcium mediated 
or that a yet unknown endosome functions in secretion of active cathepsin B 
(Rodriguez et al., 1997; Linebaugh et al., 1999; Andrews, 2000).  Procathepsin B 
secretion is thought to be independent of the secretory lysosome theory, i.e., 
secretion of active cathepsin B.  Procathepsin B is secreted through the default 
pathway as a result of the high levels of expression in tumors and swapping of 
available MPRs (Roshy et al., 2003). 
 
Molecular Regulation of Cathepsin B.  Molecular regulatory 
mechanisms controlling the biosynthesis of cathepsin B may play a role in the 
divergent protein trafficking seen in malignancy.  Gene amplification, increased 
transcription, mRNA stability, use of alternative promoters, and alternative 
splicing have all been shown to affect the levels and/or localization of cathepsin 
B protein in pathologies [for review, see (Yan and Sloane, 2003)].  These 
molecular changes at the genetic level resulting in elevated protein, aberrant 
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localization, secretion, and in turn greater activity of cathepsin B, have been 
noted in several tumor types such as brain, colorectal, lung and prostate (Yan et 
al., 1998; Koblinski et al., 2000).  
The cathepsin B transcript consists of at least 13 exons (Berquin et al., 
1995).  The 5’-untranslated region includes exons 1, 2, and 25 bp of exon 3.  
Translation of the preproprotein sequence begins at the initiation site within exon 
3 and ends in exon 11, where the stop codon resides.  The remainder of exon 11 
and 12 constitute the non-coding 3’-untranslated region.  Cao et al. were the first 
to isolate full-length preprocathepsin B cDNA clones from a human tumor source 
(Cao et al., 1994).  In a later study, the same cDNA clones were assessed for 
any structural modifications that might result in membrane association and 
secretion of cathepsin B.  Two new exons (exon 2a and exon 2b) and multiple 
transcription initiation sites in the 5’-UTR were identified (Berquin et al., 1995).  
The region upstream of exon 1 is high in GC content and lacks TATA and CAAT 
boxes, characteristics of a housekeeping-type promoter.  This suggests that the 
cathepsin B gene may be constitutively expressed.  This does not exclude the 
possibility of transcriptional regulation at the cathepsin B promoter.  Cathepsin B 
expression and activity levels differ among tissue types or between normal and 
malignant tissues suggesting tissue specific regulation (San Segundo et al., 
1986; Qian et al., 1989; Shuja et al., 1991).  Within a region 200 base pairs 
upstream of the initiation site there are six Sp1, four Ets, and one USF (E box) 
binding sites (Jane et al., 2002).  The presence of these additional elements may 
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induce transcription at the cathepsin B promoter.  Sp1 and Ets factors regulate 
expression of cathepsin B in glioma (Yan et al., 2000).  The same transcription 
factors, e.g., Ets1, that regulate expression of cathepsin B in glioma are also 
associated with components of a proteolytic cascade in this case uPA and 
caspase 3 (Delannoy-Courdent et al., 1998; Liu et al., 2002b). 
 
Cathepsin B in Malignancy.  Pathologies associated with cathepsin B 
include inflammatory airway diseases, acute pancreatitis, arthritis, and cancer 
[for reviews, see (Reinheckel et al., 2001; Vasiljeva et al., 2007; Reiser et al., 
2010).  Protease activity is important for tumor cell invasion and the many steps 
of tumor progression.  Cathepsin B and other proteases function in the cleavage 
of enzymes secreted as inactive precursors, degradation of the basement 
membrane, invasion of surrounding tissues, and also angiogenesis.  There is a 
substantial literature that supports a functional role for cathepsin B in malignancy 
[for reviews, see (Gocheva et al., 2006; Mohamed and Sloane, 2006). 
Cathepsin B expression and/or its activity is increased in several tumor 
types.  These include carcinomas of the breast (Krepela et al., 1989), colon 
(Campo et al., 1994), prostate (Sinha et al., 1995), lung (Sukoh et al., 1994) and 
stomach (Watanabe et al., 1989), gliomas (Rempel et al., 1994), and melanomas 
(Sloane et al., 1981).  As is true for matrix metalloproteinases (MMPs) and serine 
proteases (van Kempen et al., 2002; Netzel-Arnett et al., 2003), tumor stromal 
interactions influence the expression and secretion of cathepsin B. Not only 
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tumor cells, but also other cells present in the tumor microenvironment, such as 
inflammatory macrophages and fibroblasts, exhibit elevated levels of cathepsin B 
(Campo et al., 1994; McKerrow et al., 2000).  Our laboratory determined that 
growth of human breast fibroblasts on collagen I alters cell morphology and 
increases cathepsin B expression and secretion of procathepsin B (Koblinski et 
al., 2002).  In agreement with these findings Klose et al have observed that 
cathepsin B protein levels and cellular localization are affected when high-
invasive melanoma cells were cultured with collagen I, (Klose et al., 2006).  
Increases in expression of uPA and MMPs are also observed when epithelial 
cells, malignant cells, and stromal cells are cultured on various extracellular 
matrices (Mauch et al., 1989; Khan and Falcone, 1997; Bafetti et al., 1998).  
Thus, findings from several studies suggest that cell-matrix interactions play a 
pivotal role in the regulation, localization, and activity of cathepsin B and many 
other proteinases. 
Cathepsin B cleaves a plethora of targets in the tumor mircoenvironment.  
For example, cathepsin B is capable of degrading ECM components such as 
type IV collagen, fibronectin, and laminin.  The activity of cathepsin B, like other 
tumor promoting proteases, has a more complex function in malignant 
progression than once thought.  Mature active cathepsin B is capable of 
converting these zymogens into their active derivatives: pro-MMP-3 (Murphy et 
al., 1992), and pro-uPA (Kobayashi et al., 1991).  On the other hand, 
procathepsin B activators include cathepsin D (van der Stappen et al., 1996), 
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cathepsin G, tPA, uPA, and the elastases (Dalet-Fumeron et al., 1993; Dalet-
Fumeron et al., 1996).  Cathepsin B can also undergo glycosaminoglycan 
facilitated autoactivation (Caglic et al., 2007).  Finally, cathepsin B, by 
inactivation of endogenous protease inhibitors, indirectly increases the activity of 
other proteases.  For example, TIMP-1 and TIMP-2, the tissue inhibitors of matrix 
metalloproteinases, and the serine protease inhibitor, antileukoproteinase, are 
degraded by cathepsin B (Kostoulas et al., 1999; Taggart et al., 2001).  
 Cathepsin B participates in a complex proteolytic network to regulate 
tumor progression [for review, see (Mason and Joyce, 2011)].  Moreover, 
pericellular proteolytic pathways and signaling pathways converge to specific 
regions on the cell surface, named caveolae.  The annexin II tetramer, cathepsin 
B, uPAR, uPA, and β1 integrin all localize to caveolae on the cell surface [for 
review, see (Sloane et al., 2005)].  Not only do these proteins localize to 
caveolae, they also facilitate interactions of their binding partners.  Associations 
between S100A10, the light chain of the AIIt, with both pro-cathepsin B and 
plasminogen have been reported (Kang et al., 1999; Mai et al., 2000).  The 
heavy chain, annexin II, is a collagen I binding protein (Santoro et al., 1994).  
Also, the uPA:uPAR protein complex was shown to act as a ligand of β1 integrin 
in Chinese hamster ovary cells (Tarui et al., 2003).  Secretion and cell surface 
association of both pro- and active cathepsin B observed in malignancy favor 
conditions for its involvement in tumor invasion as well. 
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Cathepsin B may play causal roles in tumor growth, not just invasion and 
metastasis. Growth factors, such IGFs, FGFs, and TGF-βs, associated with ECM 
components, control cell proliferation, differentiation, and synthesis of the 
extracellular matrix.  Cathepsin B remodeling of the extracellular matrix (ECM) 
could influence the release of growth factors from matrix storage and even their 
activation (Taipale and Keski-Oja, 1997). For example, cathepsin B proteolysis of 
thyroglobulin mediates thyroid hormone liberation in thyroid epithelial cells (Brix 
et al., 1996). 
 
uPA and uPAR: Components of the Plasminogen Activation System.  
The urokinase plasminogen activating system is a serine protease family 
including uPA, its glycosyl phosphatidyl inositol-anchored receptor uPAR, soluble 
uPAR, uPAR associated protein, plasminogen and the two inhibitors of the serine 
proteinase inhibitor superfamily, plasminogen activator inhibitor-1 and -2.  This 
system is important for wound healing, tissue regeneration, immune response 
and multiple aspects of neoplastic progression including cell adhesion, ECM 
degradation and remodeling, migration, metastasis, growth at secondary tumor 
site and neoangiogenesis [for reviews, see (Choong and Nadesapillai, 2003; 
Duffy, 2004; Ulisse et al., 2009)].  uPA is secreted as a zymogen or pro-uPA and 
binds to its receptor, uPAR, on the cell surface.  Pro-uPA is processed to an 
active two-chain form consisting of the uPAR binding A chain and catalytically 
active B-chain (Robison and Collen, 1987; Gurewich, 2000).  Biological activity of 
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uPA is highly dependent on its binding to uPAR.  However, uPA-mediated 
activation of plasmin and MMPs occurs in uPAR-deficient mice (Carmeliet et al., 
1998).  uPAR-independent effects of uPA also include mitogenic stimulation of 
quiescent melanoma cells  (Koopman et al., 1998).  Proteolytic cleavage of 
plasminogen, the primary substrate of uPA, generates the serine protease 
plasmin (Rickli, 1975), which in turn activates uPA, creating a feedback activation 
loop between these proteases.  The key physiological role of plasmin is 
fibrinolysis (Robison and Collen, 1987), but it also degrades ECM components 
and activates MMPs in processes of angiogenesis and metastasis (Pepper, 
2001; Rabbani and Mazar, 2001).   
 The plasminogen activation system is directly involved in metastatic 
spread and reduced patient survival in breast cancer [for review, see (Han et al., 
2005).  More than 20 years ago uPA was first suggested as a marker of 
aggressive breast cancer (Duffy et al., 1988).  Since then many studies have 
corroborated that uPA and uPAR are highly expressed in breast cancer patient 
samples and are predictive of poor outcome (Grondahl-Hansen et al., 1995; 
Grondahl-Hansen et al., 1997; Foekens et al., 2000).  Plasminogen activation 
and cell surface binding is regulated by uPA in breast cancer cells of high 
invasive potential (Stillfried et al., 2007).  In this study, the authors suggest that 
uPA is a therapeutic target for the treatment of aggressive breast cancer.  In 
addition to malignant epithelial breast tissue, the plasminogen activation system 
is also associated with stromal components of the tumor microenvironment, such 
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as macrophages (Pyke et al., 1993), myofibroblasts (Nielsen et al., 1996) and 
endothelial cells (Nielsen et al., 2001).  MMTV-PymT transgenic mice deficient in 
either uPA or plasminogen exhibit reductions in tumor cell spread to lymph nodes 
and decreased lung metastasis (Bugge et al., 1998; Almholt et al., 2005).                    
    
Significance and Overall Hypothesis.  My focus was to identify factors 
that cause the aggressiveness and progression of IBC.  Caveolae at the surface 
of IBC cells may be involved in initiation of proteolytic pathways as a result of the 
convergence of the plasminogen cascade with activation of the cysteine protease 
cathepsin B.  My overall hypothesis was that cell surface association of the 
cysteine protease cathepsin B, the serine proteases of the plasminogen cascade 
and their binding partners in caveolae enhance cell surface proteolysis, and 
ultimately, the aggressiveness of IBC cells. To test this hypothesis, I proposed 
the following Specific Aims: 
 
1:  Determine whether there is active cathepsin B at the surface of 
IBC cells.  Breast cancer invasion has been linked to proteolytic activity at 
the tumor cell surface.  My working hypothesis is that active cathepsin B 
localized to specialized regions of the cell surface, caveolae, contributes 
to the aggressive IBC phenotype.  We tested this hypothesis by treating 
IBC cells with a highly selective cell impermeable cathepsin B inhibitor and 
monitoring pericellular proteolysis by and invasion of IBC cells. 
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2:  Determine whether targeting caveolae, a specialized lipid raft, by 
knockdown of the expression of caveolin-1 in IBC cells alters their 
aggressive phenotype.  My working hypothesis is that caveolae are a 
functional component of the IBC phenotype.  We tested this hypothesis by 
knocking down the expression of caveolin-1 in the SUM149 IBC cell line. 
We assessed how downregulation of caveolin-1 affected degradation of 
ECM proteins, invasion through rBM and localization of proteins, including 
those of proteolytic pathways that are associated with caveolae in other 
cancer cells. 
 
3:  Determine whether targeting lipid rafts by treating IBC cells with 
lovastatin alters their aggressive phenotype.  My working hypothesis is 
that lipid rafts are a functional component of the IBC phenotype.  
Therefore, cholesterol depletion by treatment of IBC cells with a statin 
drug (i.e., lovastatin) through the disruption of lipid microdomains, 
including caveolae, will affect the IBC phenotype.  We tested this 
hypothesis by treating IBC cell lines with lovastatin and monitored 
degradation of ECM proteins, invasion through rBM and localization of 
proteins, including those of proteolytic pathways that are associated with 
caveolae in other cancer cells. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
Materials and Reagents.  Tissue culture media and supplements:  Ham’s 
F-12 medium was purchased from Mediatech  (Manassas, VA); insulin, 
hydrocortisone, ethanolamine, HEPES, 3,3′,5-triiodo-L-thyronine sodium salt, 
sodium selenite, bovine serum albumin and antibiotics (penicillin/streptomycin) 
from Sigma (St. Louis, MO); fetal bovine serum (FBS) from HyClone (Logan, 
UT); trypsin-EDTA from GIBCO (Grand Island, NY); and the reconstituted 
basement membrane Cultrex from Trevigen (Gaithersburg, MD).  Antibodies:  
Monoclonal antibodies: β1-integrin was a kind gift from Dr. Kenneth Yamada 
(National Institute of Dental and Craniofacial Research, National Institutes of 
Health, Bethesda, MD); uPA and uPAR from American Diagnostica Inc. 
(Stamford, CT); transferrin receptor from Invitrogen (Carlsbad, CA); β-tubulin 
from the Developmental Studies Hybridoma Bank (National Institute of Child 
Health and Human Development, University of Iowa, Iowa City, IA); and p36 and 
p11 from BD Biosciences (Bedford, MA).  Polyclonal antibodies: uPA and uPAR 
were purchased from Abcam (Cambridge, MA) and caveolin-1 from BD 
Biosciences.  The polyclonal antibody to cathepsin B was developed and 
characterized in our laboratory (Moin et al., 1992).  Horseradish-peroxidase-
labeled goat anti-mouse and goat anti-rabbit IgG secondary antibodies were from 
Pierce (Rockford, IL).  The anti-rabbit Alexa Fluor 488 and donkey anti-mouse 
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Alexa Fluor 555 were from Invitrogen.  Other: Normal donkey serum, saponin, 
doxycycline, Triton X-100, octylglucoside, dimethyl sulfoxide (DMSO), puromycin, 
hexadimethrine bromide (polybrene), filipin III, lovastatin and all other chemicals 
unless otherwise stated were from Sigma; (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), 4’,6-diamidino-2-phenylindole-
dihydrochloride (DAPI), Hoechst 33342 and DQ-collagen IV were from 
Invitrogen; benzyloxy-carbonyl-L-arginyl-L-arginine-4-methyl-7-coumarylamide 
(Z-Arg-Arg-NHMec) was from Bachem (Torrance, CA); the cathepsin B inhibitor, 
N-(l-3-trans-propyl-carbamoyloxir-ane-2-carbonyl)-L-isoleucyl-L-proline (CA074), 
was from Peptides International (Louisville, KY); formaldehyde from 
Polysciences, Inc. (Warrington, PA); acrylamide and nitrocellulose membranes 
were from BioRad (Hercules, CA); Ultrafree-0.5 PBGC Centrifugal Filter Units 
with 5 kDa molecular weight cut off Biomax Membranes (Millipore, Billerica, MA); 
micro-bicinchoninic acid (BCA) reagents were from Pierce (Rockford, IL); 
enhanced chemiluminescent immunoblotting detection kit was from PerkinElmer 
(Waltham, MA); OpenBiosystems TRIPZ shRNAmir Lentiviral Packaging system 
and Non-silencing TRIPZ Lentiviral Inducible shRNAmir control particles were 
from Open Biosystems, Thermo Fisher Scientific (Huntsville, AL); 8.0 µm 
transparent PET membranes from BD Biosciences (Franklin Lakes, NJ); 
DakoCytomation EnVision + Dual Link System-HRP (DAB +) were from Dako 
(Carpinteria, CA); Permount® from Fisher Scientific (Pittsburgh, PA); and Diff-
Quik Stain Set was from Dade Behring (Newark, DE).   
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Cell Lines and Tissue Culture.  SUM149 and SUM190 human IBC cell 
lines (a kind gift of Dr. Stephen Ethier, Wayne State University, Detroit, MI) and 
the human IBC cell line, MDA-IBC-3 (provided by Dr. Wendy A. Woodward, The 
University of Texas MD Anderson Cancer Center, Houston, TX), were cultured 
as originally specified (Neve et al., 2006; Klopp et al., 2010) in Hams F-12 media 
containing 5 mg/ml insulin, 1 mg/ml hydrocortisone, antibiotics 
(penicillin/streptomycin) and 5% (SUM149), 2% (SUM190) or 10% (MDA-IBC-3) 
FBS.  Media for SUM190 cells were further supplemented with 5 mM 
ethanolamine, 10 mM HEPES, 5 mg/ml transferrin, 6.6 ng/ml 3,3′,5-triiodo-L-
thyronine sodium salt, 8.7 ng/ml sodium selenite and 1 mg/ml bovine serum 
albumin. All cells were maintained in 5% CO2/humidified atmosphere at 37°C 
with the media changed every two days. 
All IBC cell lines were maintained and grown as a monolayer in tissue 
culture flasks.  During log phase growth, cells were first washed twice with 
phosphate buffered saline (PBS).  For dissociation of cells from the culture flask, 
0.25% trypsin-EDTA was added and cells were incubated at 37°C for either 2 
minutes (SUM190 and MDA-IBC-3 cells) or 4 minutes (SUM149 cells).  The cells 
were then washed with 4 volumes of growth medium, transferred to a 15-ml 
conical tube and centrifuged at 100 x g for 5 min.  The media were aspirated and 
the cell pellet resuspended in an appropriate amount of fresh growth media.  
Cells were seeded in a new tissue culture flask.  IBC cells were typically split at a 
ratio of 1:3. 
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Preparation of cell lysates and conditioned media.  IBC cells were 
grown on plastic to 70% confluency and then serum-starved overnight.  
Conditioned media were collected and centrifuged at 100 x g at 4 °C to remove 
whole cells, and then re-centrifuged at 800 x g at 4 °C to remove cell debris.  All 
conditioned media samples were concentrated to equal volumes in Ultrafree-0.5 
PBGC Centrifugal Filter Units with 5 kDa molecular weight cut-off Biomax 
Membranes.  Cells were harvested in lysis buffer (10 mM Tris, pH 7.5, 150 mM 
NaCl, 1% Triton X-100, 60 mM octylglucoside) and then passed ten times 
through a syringe with a 20-gauge needle and centrifuged for 5 minutes at 
10,000 x g at 4°C.  Supernatants were recovered and protein concentrations 
were quantified using micro-BCA reagents according to the manufacturer’s 
instructions. 
 
Preparation of 3D reconstituted basement membrane (rBM) overlay 
cultures.  Sixty-mm dishes were coated with 300 µl of rBM (Cultrex) and allowed 
to solidify for 15 min at 37 °C.  Suspensions of single cells (1 x 106) were seeded 
on top of solidified rBM and grown in complete media containing 2% rBM. Within 
24 hours, cells formed 3D spheroid structures. 
 
Subcellular fractionation.  Non-detergent and detergent based protocols 
were used to prepare caveolae-enriched membrane fractions of IBC cells 
(Cavallo-Medved et al., 2009).  In the non-detergent based method, cells grown 
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as a 2-dimensional (2D) monolayer on plastic (4 x 100-mm dishes) and in 3-
dimensions (3D) on rBM (4 x 60-mm dishes) for 2 and 5 days, respectively, were 
washed with PBS and collected into 500 mM sodium carbonate buffer, pH 11.0.  
Cells were homogenized in a Dounce homogenizer on ice and sonicated three 
times for 10 seconds each.  A discontinuous sucrose gradient was prepared as 
previously detailed (Cavallo-Medved et al., 2009).  Briefly, the cell homogenate 
was mixed thoroughly with an equal volume of 90% (w/v) sucrose, then overlaid 
with 35% (w/v) sucrose and 5% (w/v) sucrose and subsequently centrifuged 
(185,000 x g) for 19 hours at 4 °C.  One ml fractions were collected and equal 
volumes of fractions 3-11 were analyzed by SDS-PAGE and immunoblotting 
(Figure 2.1). 
A successive detergent based method of cell fractionation was also 
employed to separate Triton X-100-soluble (TS) and –insoluble (TI) membrane 
fractions (Solomon et al., 1998).  3D cultures were prepared and grown, as 
described above, for 2 days and thereafter washed with cold PBS, incubated with 
300 µl of lysis buffer containing 1% Triton X-100 for 20 minutes on ice, and 
collected and centrifuged at 14,000 x g for 10 min at 4 °C.  The supernatant (TS 
fraction) was collected and the pellet was resuspended in 300 µl of lysis buffer 
containing 1% Triton X-100 plus 60 mM octylglucoside, incubated on ice for 20 
minutes, passed through a syringe with a 21.5-gauge needle and centrifuged at 
14,000 x g for 10 min at 4 °C.  The supernatant (TI fraction) was recovered 
(Figure 2.2.). 
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Figure 2.1.  Schematic for isolation of caveolae enriched fractions from IBC 
cells, using non-detergent based lysis followed by subcellular fractionation 
on a sucrose gradient. 
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Figure 2.2.  Schematic for isolation of caveolae-enriched fractions from IBC 
cells, using detergent based lysis followed by subcellular fractionation. 
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SDS-PAGE and immunoblotting.  Samples were equally loaded and 
separated by SDS-PAGE (10 or 12%) under either reducing or non-reducing 
conditions, transferred to a nitrocellulose membrane, blocked and immunoblotted 
with primary antibodies against human cathepsin B (1:4000), β1-integrin 
(1:3000), uPA (1:2000), uPAR (1:2000), caveolin-1 (1:4000) or β-tubulin (1:1500) 
in TBS buffer (20 mM Tris, pH 7.5, 0.5 M NaCl) containing 0.5% Tween 20 and 
5% (w/v) non-fat dry milk.  After washing, membranes were immunoblotted with 
secondary antibodies conjugated with horseradish peroxidase (1:10,000).  After 
washing, bound antibodies were detected by enhanced chemiluminescence 
according to the manufacturer's instructions. 
 
Cathepsin B activity assay.  Cathepsin B activity was measured using 
the synthetic fluorometric substrate Z-Arg-Arg-NHMec, as previously described 
(Cavallo-Medved et al., 2003).  Briefly, equal-volume aliquots of TS and TI 
fractions were incubated with activator buffer for 15 minutes at 37 °C.  Following 
this activation step, 150 mM Z-Arg-Arg-NHMec (pH 6.0) was added to the assay 
buffer and fluorescence was measured in triplicate, at one-minute intervals over 
a 30 minutes period, at an excitation of 360 nm and an emission of 465 nm. 
 
Live-cell proteolysis assay.  Proteolytic cleavage of DQ-collagen IV by 
live IBC cells was imaged in real time and quantified, as previously described 
(Jedeszko et al., 2008; Sameni et al., 2009).  Briefly, IBC cells (2.5 x 104) were 
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seeded on round glass coverslips coated with rBM containing 25 mg/ml DQ-
collagen IV substrate and incubated at 37 °C for 40 minutes to allow for cell 
attachment.  Complete media containing 2% rBM was then added to the cultures 
and grown for 24 to 48 hours.  Live cells were pretreated with Hoechst 33342 
nucleic acid stain and imaged with a Zeiss LSM 510 META NLO confocal 
microscope, equipped with an incubator (37 °C and 5% CO2) surrounding the 
microscope stage, using a 40X Plan neofluar (N.A., 0.7) objective.  DQ-collagen 
IV cleavage products were observed as green fluorescence (Figure 2.3).  Where 
specified, the assay was performed in the presence of 10 mM CA074, a highly 
selective cathepsin B inhibitor (Murata et al., 1991). 
 
Invasion assay.  Cell culture inserts [8.0 µm transparent PET 
membranes], were coated with 2 mg/ml rBM and incubated in a 24-well plate at 
room temperature to permit rBM solidification.  Complete media, the stimulant for 
invasion, was added to the bottom of each well.  SUM149 cells (5.0 x 104) in 
serum-free media were seeded onto the rBM-coated inserts and incubated for 24 
h at 37 °C in the presence of DMSO (vehicle control) or 10 µM CA074.  Cells that 
had not invaded were removed with a cotton swab.  Cells that had invaded were 
fixed with 3.7% formaldehyde, stained with DAPI and imaged at 20X 
magnification with a Zeiss Axiophot conventional epifluorescent microscope.  Ten 
random microscopic fields per filter were analyzed.  The number of cells that
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Figure 2.3. Cartoon depicting imaging of live cell proteolysis by confocal 
microscopy.  IBC cells are grown in rBM containing DQ-collagen IV. Using a 
water-immersion dipping objective, optical sections as depicted by the gray 
rectangles are acquired throughout the entire volume of the 3D cellular 
structures.  
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invaded was assessed by counting nuclei with MetaMorph™ image analysis 
software (Molecular Devices, Sunnyvile, CA). 
 
Immunocytochemical staining.  Intracellular co-staining was performed 
at room temperature on 2D (permeabilized with 0.1 % saponin) and 3D cultures 
(permeabilized with 0.2% Triton X-100).  In our experience, Triton X-100, a mild 
detergent, is better than saponin for permeabilizing cells grown in 3D cultures. 
The cultures were fixed with 3.7% formaldehyde and incubated with the following 
primary antibodies diluted in 0.2% Triton X-100/PBS: rabbit anti-caveolin-1 
(1:50), mouse anti-uPA (1:25), and mouse anti-uPAR (1:12.5).  Secondary 
antibodies [donkey anti-rabbit Alexa Fluor 488 and donkey anti-mouse Alexa 
Fluor 555] were diluted (1:5000) in 0.2% Triton X-100/PBS plus 5% normal 
donkey serum.  All immunocytochemical staining was imaged on a Zeiss LSM 
510 META NLO confocal microscope using either a 100X oil Plan neofluar (N.A., 
1.3) objective (2D cultures) or 40X Plan apofluar (N.A., 0.7) objective (3D 
cultures). 
 
Immunohistochemical (IHC) staining of patient samples.  Institutional 
review board approval from Ain Shams University ethics committee and the 
National Cancer Institute, Cairo University along with patient consent forms were 
obtained for the purpose of patient enrollment in this study.  Inclusion criteria for 
patients included clinical, mammographic, ultrasound and pathological diagnosis 
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according to the American Joint Committee on Cancer T4 d designation for IBC 
(Dawood et al., 2011). Pre-treated formalin fixed paraffin embedded IBC (n = 23) 
and non-IBC (stage II-III, n = 27) patient tissue samples were subjected to IHC 
analysis (Nouh et al., 2011).  Briefly, tissue sections were incubated for one hour 
at room temperature with either monoclonal anti-caveolin-1 (1:150) or polyclonal 
anti-cathepsin B (1:500) primary antibodies.  A second incubation was performed 
with HRP rabbit/mouse [EnVision + Dual Link System-HRP (DAB +)] for 45 
minutes.  Nuclei were counterstained with hematoxylin, sections were mounted 
with Permount® and imaged with an Olympus, CX41 light microscope.  Patient’s 
pathological evaluation, IHC and scoring analysis were done in collaboration with 
a group at Cairo University.  We performed the statistical analysis for this study.     
 
MTT proliferation assay.  IBC cells were seeded (5,000 per well) in 96-
well plates and cultured overnight.  On day one, cells were treated with 3 µM 
lovastatin or vehicle (DMSO) containing 200 µl of growth media and cultured for 
24, 48 and 72 h.  Fifty microliters of MTT stock solution (5 mg/ml) was added to 
each well and incubated for 3 h at 37 °C allowing the production of formazan by 
living cells.  The media was subsequently removed and 150 µl of DMSO was 
added to each well and plates were placed on a shaker to dissolve the formazan 
for 40 minutes at room temperature.  Absorbance values were measured in 
triplicate at a 485 nm wavelength using a SpectraFluor Plus (Teccan, Salzburg, 
Austria). 
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Filipin III staining.  Cells grown in monolayer on round glass coverslips 
and treated for 24 h with 3 µM lovastatin or vehicle were washed 3 times with 
PBS.  Cells were fixed with 3.7% formaldehyde solution for 15 minutes at room 
temperature.  After washing, the fixed cells were incubated with Filipin III (stock 
solution of 5 mg/ml diluted 1:150 in 4% bovine serum albumin/PBS) for 2 hours.  
Stained cells were imaged on a Zeiss LSM 510 META NLO confocal microscope 
using a 63X oil Plan neofluar (N.A., 1.3) objective. 
 
Lentiviral Transduction of SUM149 cells.  Knockdown of caveolin-1 
gene expression was carried out using the OpenBiosystems TRIPZ shRNAmir 
Lentiviral Packaging system.  For lentivirus production, HEK293T (Open 
Biosystems) cells were cultured in Dulbecco’s modified Eagles medium 
containing 10% FBS without antibiotics in 35-mm dishes to 100% confluence.  
The cells were then transfected with 5.7 µg of TransLenti Viral Packaging Mix 
(pTLA1-Pak, pTLA1-Enz, pTLA1-Env, PTLA1-Rev and pTLA1-TOFF) and 1.8 µg 
of each pTRIPZ CAV1 shRNA transfer vector with 37.5 µg of Arrest-In 
transfection reagent.  HEK293T cells were incubated for 6 hours at 37 °C and 5% 
CO2 and the medium was changed to fresh culture medium without antibiotics 
and placed in an incubator set at 32 °C and 5% CO2 for 24 hours to produce 
viruses.  Subsequently the viral broth was harvested and centrifuged at 1000 rpm 
for 5 minutes.  SUM149 cells (25,000 per well) were seeded in a 12-well plate, 
treated with 6 µg/ml polybrene and infected with virus collected from HEK293T 
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cells 24, 48 and 72 h post-transfection for 3 rounds of infection.  Media was then 
changed to complete growth medium of SUM149 cells containing 1 µg/ml 
puromycin and 500 ng/ml doxycycline. 
 
Statistical Analysis. A two-tailed, assuming equal variance, Student’s t-
test was executed to determine the statistical significance of differences in live 
cell proteolysis and invasion assays. P values for the relationship between 
cathepsin B expressing breast carcinoma cells, of both IBC and non-IBC, and 
caveolin-1 protein expression were assessed with a chi-square test.   
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CHAPTER 3 
 
RESULTS 
 
Caveolin-1, β1-integrin and uPAR expression are higher in SUM149 
than in SUM190 cells.  Caveolin-1 and β1-integrin form a trimeric complex with 
uPAR within caveolae (Schwab et al., 2001), a complex that mediates cell 
adhesion and migration.  Therefore, we compared expression of caveolin-1 and 
β1-integrin in SUM149 and SUM190 cells.  There was a striking dissimilarity in 
levels of the two proteins (Figure 3.1A), The cell surface receptor for uPA is 
uPAR (Vassalli et al., 1985; Cubellis et al., 1986), a GPI-anchored membrane 
glycoprotein that has been localized to caveolae in a wide variety of cells (Wei et 
al., 1999; Schwab et al., 2001; Cavallo-Medved et al., 2005).  We found that 
SUM149 cells expressed more receptor than did SUM190 cells (Figure 3.1A), 
paralleling the difference in expression of caveolin-1 and β1-integrin.  These data 
suggest that pericellular proteolysis by the two cell lines may not be the same 
due to the observed differences in cav-1, uPAR and β1-integrin expression and 
thus the potential to localize pro-uPA and a caveolae-associated protease known 
to activate pro-uPA, i.e., cathepsin B, at the cell surface. 
 
Cathepsin B and uPA expression and secretion are similar in 
SUM149 and SUM190 cells.  Cathepsin B has been linked to both pericellular 
and intracellular proteolysis in breast cancer cells (Sameni et al., 2000).  Our
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Figure 3.1.  Expression of cathepsin B, uPA, uPAR, β1-integrin and 
caveolin-1 in SUM149 and SUM190 IBC cells.  Duplicate samples of cell 
lysates (intracellular) and conditioned media (secreted) from 2D cultures of 
SUM149 and SUM190 cells were resolved by SDS-PAGE.  Proteins were 
transferred to a nitrocellulose membrane and immunoblotted with (A) anti-E 
cadherin, anti-uPAR, anti-β1-integrin, anti-caveolin-1 (cav-1) antibodies; (B) anti-
β-tubulin antibody as a loading control; (C) an anti-cathepsin B (CTSB) antibody 
[bands represent proform (43 kDa), intermediate (38 kDa), single chain mature 
(31 kDa), and heavy chain of double chain mature (25/26 kDa) cathepsin B] and 
(D) an anti-uPA antibody.  
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previous in vitro findings demonstrate that monocytes, an inflammatory 
component associated with IBC, stimulate the invasive potential and degradation 
of ECM proteins by SUM149 IBC cells (Mohamed et al., 2008).  These results 
correlate with increased cathepsin B expression and activity in the SUM149 cells.  
Recent in vivo studies have also identified cathepsin B as a potential prognostic 
marker for IBC (Nouh et al., 2011).  Here we examined two IBC cell lines, 
SUM149 and SUM190, for expression of cathepsin B protein.  We found that the 
two cell lines express comparable levels of the mature single chain (31 kDa) and 
double chain (25/26 kDa heavy chain + 5 kDa light chain) forms of cathepsin B in 
cell lysates and secrete comparable levels of procathepsin B (43 kDa) into the 
media (Figure 3.1C).  A 38 kDa intermediate form of the enzyme was present 
only in lysates of the SUM149 cells and mature double chain cathepsin B was 
secreted only from SUM190 cells (Figure 3.1C); these differences between the 
two cell lines are likely due to variations in the extent of processing of the 
proenzyme into the various mature forms.  We have observed similar differences 
in a variety of human tumor tissues (Moin et al., 1992). Since cathepsin B 
activates both soluble and cell surface bound pro-uPA (Kobayashi et al., 1991; 
Kobayashi et al., 1992; Kobayashi et al., 1993; Guo et al., 2002), we also 
compared the expression of uPA in the two IBC cell lines.  Both expressed 
similar levels of intracellular pro-uPA; however, secretion of pro-uPA from the 
SUM149 cell line was slightly higher (Figure 3.1D). 
 
	  	  
42 
IBC cells express E-cadherin.  Normal epithelium is highly organized 
and exhibits polarity due largely to E-cadherin-mediated cell:cell interactions 
called adherens junctions.  Deregulation of E-cadherin is a criterion for epithelial-
mesenchymal transition (EMT), which often accompanies malignant initiation and 
progression (Hirohashi, 1998).  Inactivation of adherens junctions in human 
cancer is mediated by genetic modification of adherens associated proteins, e.g., 
E-cadherin and catenins (Oda et al., 1994; Oyama et al., 1994), decreased 
expression of E-cadherin (Birchmeier and Behrens, 1994) and aberrant 
phosphorylation of β-catenin resulting in activation of cancer promoting signaling 
pathways (Schmalhofer et al., 2009).  In addition, E-cadherin ectodomain 
shedding by proteases is an alternative mechanism of E-cadherin loss of 
function.  For example, cathepsin B is capable of cleaving the extracellular 
domain of E-cadherin in vitro and in vivo [Roshy, doctoral thesis and (Gocheva et 
al., 2006)].  Generally, downregulation or complete loss of E-cadherin expression 
correlates with breast cancer that is invasive, higher grade and metastatic (Berx 
and Van Roy, 2001; Vincent-Salomon and Thiery, 2003).  Elevated levels of E-
cadherin are strongly associated with IBC (Kleer et al., 2001).  In contrast, 
invasive ductal and lobular carcinomas exhibit significantly reduced expression of 
E-cadherin (Moll et al., 1993).  Kleer and colleagues suggest that expression of 
E-cadherin may facilitate the formation of IBC tumor emboli after intravasation 
into lymphatic vessels in vivo.  As expected, we found that both IBC cell lines 
expressed E-cadherin (Figure 3.1). 
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SUM149 and SUM190 cells exhibit different patterns of proteolysis of 
type IV collagen.  We used a functional live-cell proteolysis assay to assess in 
real time degradation of DQ-collagen IV by SUM149 and SUM190 cells.  DQ-
collagen IV cleavage products (green fluorescence) were present in cultures of 
both cell lines; however, there were distinct differences in localization of the 
fluorescent cleavage products (Figure 3.2).  Cleavage products were found 
adjacent to the external cell surface of the SUM149 cells, i.e., pericellularly.  In 
contrast, in the SUM190 cells a distinct punctate fluorescence pattern was 
present intracellularly, consistent with the cleavage products being in vesicles.  
This may reflect proteolysis that occurs either intracellularly in the vesicles or 
extracellularly with the degradation fragments taken up into the vesicular 
compartment by endocytosis. 
 
uPA and uPAR colocalize in caveolae-enriched fractions of SUM149 
cells.  Our laboratory utilizes two methods for purification of caveolae-enriched 
membranes, a non-detergent and a detergent based protocol.  These methods 
are employed based on the biochemical properties of caveolae: they have a light 
buoyant density and are resistant to detergent solubilization.  Since non-caveolae 
lipid rafts have similar characteristics, there is controversy over purification 
methods, however the sodium carbonate method is considered preferable (Song 
et al., 1996).  Since expression levels of caveolin-1 and uPAR were high in 
SUM149 cells and we have previously shown that uPA and uPAR colocalize in
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Figure 3.2.  Live-cell proteolysis assay revealed disparate proteolytic 
patterns in 3D cultures of SUM149 and SUM190 cells.  SUM149 and SUM190 
cells were seeded onto glass-coverslips coated with rBM containing DQ-collagen 
IV.  Following overnight incubation at 37 °C, cells and DQ-collagen IV cleavage 
products (green) were imaged using confocal microscopy (see Materials and 
Methods).  Live SUM149 and SUM190 cells grown in 3D degraded DQ-collagen 
IV pericellularly (arrowhead) and predominantly intracellularly (arrow), 
respectively. Confocal Z stack images were reconstructed in 3D utilizing 
Volocity™ software (PerkinElmer, Waltham, MA).  Representative merged 
images of DIC and green channels of the equatorial plane (middle) and two 
planes equidistant, 20 µm, from the equatorial plane (top and bottom) are also 
shown.  Bar, 20 µm. 
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caveolar fractions of colorectal carcinoma cells (Cavallo-Medved et al., 2005), we 
isolated caveolae-enriched fractions from SUM149 cells.  We used a method that 
employs a sodium carbonate buffer for cell lysis followed by subcellular 
fractionation in a sucrose density gradient (Cavallo-Medved et al., 2009).  
Analysis of caveolae-enriched fractions (i.e., fractions in which caveolin-1 was 
primarily distributed) revealed that uPA and its receptor uPAR were both present 
in these fractions (Figure 3.3A-B).  This was observed for SUM149 cells grown 
either as 2D or 3D cultures.  For cell fractionation studies, sufficient starting 
material is more readily obtained from 2D cultures.  We prefer, however, to 
analyze 3D cultures as they more closely resemble the in vivo phenotype 
(Debnath and Brugge, 2005) and have been shown to be predictive of drug 
responses in vivo (Weigelt and Bissell, 2008; Li et al., 2010).  In agreement with 
our fractionation studies, immunostaining of 2D (Figure 3.3C) and 3D (Figure 
3.3D) cultures of SUM149 cells showed that uPA and uPAR colocalized with 
caveolin-1, consistent with a role for caveolin-1 in the distribution of these 
proteins to the cell surface. 
 
Active cathepsin B is present in caveolae-enriched fractions of 
SUM149 cells.  We have previously shown, using both detergent and non-
detergent methods, that cathepsin B localizes to caveolae-enriched fractions of 
colon carcinoma and endothelial cells (Cavallo-Medved et al., 2003; Cavallo-
Medved et al., 2005; Cavallo-Medved et al., 2009).  Cathepsin B is denatured
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Figure 3.3. uPA and uPAR codistributed with caveolin-1 in subcellular 
fractions of SUM149 cells.  Isolation of caveolae from SUM149 cells grown in 
2D (A) or in 3D culture (B) was performed using a non-detergent method as 
described in Materials and Methods.  Equal-volume aliquots of fractions 3-11 
were analyzed by SDS-PAGE and immunoblotted with antibodies against uPA, 
uPAR or caveolin-1.  Merged DIC and fluorescent images are representative 
images of SUM149 2D (C) or 3D (D) cultures immunostained for caveolin-1 
(green) and uPA (red) or uPAR (red).  Colocalization of the two proteins appears 
yellow (arrows).  Confocal microscopy was performed as described in Materials 
and Methods.  Bar, 10 µm for 2D cultures; 20 µm for 3D cultures. 
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and thus is inactive in the non-detergent based method as the cells are lysed in 
sodium carbonate buffer at pH 11.  Therefore, to further assess localization of 
cathepsin B to caveolae-enriched fractions of SUM149 3D cultures, we utilized a 
detergent-based method that separates Triton X-100-soluble (TS) from –
insoluble (TI) membrane components.  Since caveolae are insoluble in 1% Triton 
X-100, the TI fraction contains caveolae and associated proteins and the TS 
fraction contains proteins from cellular components that are solubilized by the 
detergent including lysosomes.  As expected more caveolin-1 was observed in 
the TI fraction than the TS fraction (Figure 3.4A).  Caveolin-1 subcellular 
localization is not exclusive to caveolae, but is also present in the endoplasmic 
reticulum, Golgi and cytosolic where it is presumed to complex with chaperones 
or embedded in lipoprotein-like particles (Liu et al., 2002a). Mature forms of 
cathepsin B were present in the TI fractions (Figure 3.4A).  Substantially higher 
levels of mature cathepsin B were present in the TS fractions containing 
lysosomes, the predominant subcellular localization of cathepsin B.  Cathepsin B 
activity was observed in both TS and TI fractions (Figure 3.4B), at levels 
comparable to the levels of mature cathepsin B detected by immunoblotting 
(Figure 3.4A).  The enzymatic activity in the isolated TS and TI fractions was 
completely abrogated by CA074, a highly selective inhibitor for cathepsin B 
(Murata et al., 1991).  The presence of cathepsin B activity in the TI fractions 
might be consistent with a functional role for cathepsin B at the cell surface.  We 
showed that uPA and uPAR colocalize to caveolae-enriched fractions using a
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Figure 3.4.  Active cathepsin B is present in caveolae-enriched fractions of 
SUM149 3D cultures.  Caveolae from SUM149 3D cultures were isolated by a 
detergent-based method, as described in Materials and Methods, that separate 
Triton X-100-soluble (TS; non-caveolae) from Triton X-100–insoluble (TI; 
caveolae-enriched) cellular fractions.  (A) Equal volume aliquots of each fraction 
were analyzed by SDS-PAGE and immunoblotted with antibodies against 
cathepsin B or caveolin-1.  (B) TS and TI fractions were assayed for enzymatic 
activity against the synthetic cathepsin B substrate Z-Arg-Arg-NHMec.  
Cathepsin B activity in both TS and TI fractions was inhibited by 10 µM CA074. 
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non-detergent based sucrose fractionation method (Figure 3.3A-B) and obtained 
similar results by the detergent based method as well (Figure 3.5).  In addition, 
we also observed E-cadherin and β1-integrin localized to TI fractions (Figure 
3.5). 
Our laboratory identified p11, the light chain of the annexin II tetramer, as 
a binding partner for procathepsin B in vitro (Mai et al., 2000).  Procathepsin B 
via its interaction with the light chain of the annexin II tetramer is bound to the 
surface of tumor cells.  Cathepsin B, p11, and p36 have all been identified in 
caveolae-enriched membrane fractions of the human colon carcinoma cell line 
HCT 116 (Cavallo-Medved et al., 2003).  Using SUM149 cells, we were also able 
to show that p36 and p11, the cathepsin B binding partner, localized to caveolae-
enriched fractions in these cells (Figure 3.5). 
 
Inhibition of cathepsin B reduces type IV collagen degradation and 
invasion by IBC cells.  The live-cell proteolysis assays indicated that SUM149 
cells degrade DQ-collagen IV pericellularly.  Our subcellular fractionation and 
enzymatic assays indicated that active cathepsin B is associated with caveolae-
enriched fractions and therefore on the surface of SUM149 cells.  Thus, we 
examined whether inhibiting cathepsin B would reduce pericellular degradation of 
DQ-collagen IV.  For these cell-based assays, we used CA074, the highly 
selective cathepsin B inhibitor that is cell-impermeant (Murata et al., 1991) and 
thus would only reduce cathepsin B activity outside the SUM149 cells.  We used 
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Figure 3.5.  E-cadherin, β1-integrin, uPA, uPAR, p36 and p11 are localized 
to caveolae-enriched fractions of SUM149 3D cultures. Caveolae enriched 
fractions were isolated by a detergent based method that separates Triton X-100-
soluble (TS) from –insoluble (TI) membrane components.  TS indicates non-
caveolae fractions and TI indicates caveolae-enriched fractions.  Equal volumes 
of each fraction were analyzed by SDS-PAGE and immunoblotted with anti-E-
cadherin, anti-β1-integrin, anti-uPA, anti-uPAR, anti-caveolin-1, anti-p36, anti-p11 
and anti-transferrin receptor (TfR) antibodies.  TfR is a negative control as it is 
not associated with lipid rafts. 
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our previously established methods to quantify degradation of DQ-collagen IV on 
a per cell basis throughout the entire volume of SUM149 3D cultures (Jedeszko 
et al., 2008).  We demonstrated that CA074 significantly attenuated degradation 
of DQ-collagen IV (Figure 3.6) and invasion (Figure 3.7), suggesting that 
cathepsin B contributes to pericellular degradation and invasion by SUM149 
cells. 
 
Cathepsin B and caveolin-1 are co-expressed in IBC tissues in vivo.  
To determine whether there is an association between cathepsin B and caveolin-
1 in vivo, we immunostained paraffin-embedded tissue samples from IBC and 
non-IBC patients for cathepsin B and caveolin-1.  IBC patients in this study 
ranged in age from 29 to 60 years (mean ± SD = 41 ± 8); non-IBC patients 
ranged in age from 33 to 67 years (mean ± SD = 50 ± 9).  Tumor grade analysis 
revealed that 65% and 78% of the IBC and non-IBC samples, respectively, were 
grade I or II and 35% and 22% of the IBC and non-IBC samples, respectively, 
were grade III.  For further clinical and pathological characterization of the IBC 
and non-IBC samples, see Nouh et al. (Nouh et al., 2011).  In the IBC tissues, we 
observed strong expression of cathepsin B in tumor cells and in tumor emboli 
within dermal lymphatics and moderate expression in stromal cells (Figure 3.8A 
and B).  There was heterogeneous staining for caveolin-1 in tumor emboli (Figure 
3.8C).  Endothelial cells of dermal lymphatics containing tumor emboli stained 
strongly for caveolin-1, consistent with the known high levels of caveolae in
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Figure 3.6.  Inhibition of cathepsin B activity modestly, but significantly, 
reduced degradation of DQ-collagen IV by SUM149 3D cultures.  SUM149 
cells were grown as 3D rBM overlay cultures containing DQ-collagen IV in the 
presence of either DMSO (control) or 10 µM CA074.  Confocal Z stack images 
were captured and used to generate 3D reconstructions. (A) Representative 3D 
reconstructions of DQ-collagen IV degradation products (green), SUM149 nuclei 
(stained with Hoechst 33342, blue). (B) Corresponding intensity map (red being 
most intense and blue least intense) of DQ-collagen IV degradation products and 
corresponding DIC images (insets).  Magnification, 40X.  (C) Quantification of 
proteolysis in the entire volume of three-dimensional structures measured as the 
average integrated intensity of fluorescence per cell and expressed as percent 
control.  Results from three independent experiments are presented as mean ± 
SD; *, P< 0.02. 
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Figure 3.7.  Inhibition of cathepsin B activity significantly reduces 
invasiveness of SUM149 cells.  SUM149 cells were subjected to transwell 
invasion assays in the presence of DMSO (vehicle control) or 10 µM CA074.  (A) 
Cartoon representing setup of invasion assay. (B) Images are SUM149 cells that 
have invaded through rBM-coated filters; bar, 150 µm.  (C) Quantification of 
invaded cells was performed by counting the number of nuclei from 10 fields of 
view per filter (using Metamorph software) and expressed as percent control.  
Results from three independent experiments are presented as mean ± SD; *, P< 
0.05.  
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Figure 3.8.  Immunohistochemical staining for cathepsin B and caveolin-1 
in paraffin sections of IBC tissues.  Diffuse cytoplasmic staining for cathepsin 
B is present in tumor and stromal cells (A) and tumor emboli (B); magnification, 
40x.  (C) Caveolin-1 staining is present in tumor emboli (arrow) within dermal 
lymphatics and on the surface of dermal lymphatic endothelial cells (arrowhead); 
magnification: left panel, 10x and right panel, 40x.  
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endothelial cells (Couet et al., 2001).  Furthermore, there was a difference 
between IBC and non-IBC carcinoma cells in regard to co-expression of 
cathepsin B and caveolin-1.  Seventy percent of IBC tumor cells that express 
cathepsin B (score of ++ or +++) also expressed caveolin-1 (score of ++ or +++), 
whereas only 19% of non-IBC tumor cells showed this co-expression (P = 0.001; 
Table 3.1). 
 
Downregulation of caveolin-1 expression in IBC cells.  We 
hypothesize that downregulation of caveolin-1 will disrupt caveolae, decrease the 
cell surface association of cathepsin B and also reduce both invasion and 
degradation of extracellular matrix (ECM).  The role of caveolae and their 
structural protein caveolin-1 in breast cancer and other cancers is controversial.  
Some studies, both in vitro and in vivo, conclude that caveolin-1 functions as a 
tumor suppressor whereas others strongly support an oncogenic and 
prometastatic function for caveolin-1 [for review, see (Goetz et al., 2008)].  To 
reconcile these contradictory findings, Lloyd and Hardin (2011) have proposed a 
model in which the role played by caveolin-1 is dependent on both stage of 
disease and tumor type (Lloyd and Hardin, 2011).  Lisanti and colleagues have 
suggested at early stages of breast cancer and in some ductal carcinomas of the 
breast, caveolin-1 is a tumor suppressor (Williams and Lisanti, 2005).  On the 
other hand, in IBC, caveolin-1 is upregulated and promotes aggressiveness of 
these tumors (Perou et al., 2000; Pinilla et al., 2006).  
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Table 3.1.  Co-expression of caveolin-1 and cathepsin B in carcinoma cells 
of IBC versus non-IBC patient tissues.  Immunohistochemical scores of 0 and 
+ were considered negative and scores of ++ and +++ were considered positive.  
Data presented as number of patients (%).  Chi-square = 11.3 (degrees of 
freedom = 1). 
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High expression of caveolin-1 is a characteristic of triple-negative and other 
basal-like breast cancers (Elsheikh et al., 2008).  Triple-negative breast cancer 
(TNBC) refers to breast cancers that do not express estrogen receptor (ER), 
progesterone receptor (PR) and Her2/neu.  In addition to increased caveolin-1, 
absence of both ER and PR has been reported to be higher in IBC than non-IBC 
patient samples (Nguyen et al., 2006); hormone receptor negative breast cancers 
are known to have a worse prognosis. 
To test whether caveolae are a functional part of the IBC aggressive 
phenotype, our experimental approach was to downregulate expression of 
caveolin-1 in the SUM149 IBC cell line.  Caveolin-1 is essential to caveolae 
biogenesis (Drab et al., 2001; Razani et al., 2001).  We predict that caveolin-1 
knockdown in IBC cells will result in decreased formation of caveolae and 
decrease cathepsin B localization at the cell surface.  Knockdown of caveolin-1 in 
the SUM149 cells was carried out using the OpenBiosystems TRIPZ shRNAmir 
lentiviral packaging system.  We chose lentiviral transduction due to the high 
efficiency and stability of this technique (Stegmeier et al., 2005; Matrai et al., 
2010).  A feature of the OpenBiosystems TRIPZ system is the Tet-inducible 
promoter that regulates expression of the shRNAmir (Figure 3.9).  Therefore, 
knockdown is inducible in the presence of doxycycline, the tetracycline response 
element agonist.  In addition, the marker TurboRFP tracks expression of the 
shRNAmirs, (control and experimental).  In the absence of doxycycline the 
system is turned off thus allowing for an internal control.  OpenBiosystems also 
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Figure 3.9.  Map of TRIPZ plasmid illustrating vector elements: Tet-inducible 
promoter (TRE) for regulating expression of knockdown; TurboRFP marker 
(tRFP) to track inducible shRNAmir expression. 
  
http://www.openbiosystems.com/RNAi/shRNAmirLibraries/TRIPZlentiviralinducibl
eshR/ 
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offers a GIPZ Lentiviral shRNAmir system utilizing TurboGFP tracking shRNAmir 
expression.  This system is not compatible withour live cell proteolysis assay 
given that DQ-collagen IV degradation products fluoresce green upon proteolytic 
cleavage.  For this reason we chose to utilize the TRIPZ rather than the GIPZ 
system. 
Using six pTRIPZ constructs specific to caveolin-1, we knocked-down the 
expression of caveolin-1 by transducing SUM149 cells with lentivirus.  Figure 
3.10 lists the sequences of each clone ID and the targeting site within the 
caveolin-1 mRNA.  To produce the lentivirus, the HEK293T cells were 
transfected with each pTRIPZ construct and TransLenti viral packaging mix using 
the Arrest-In transfection reagent.  The viral broth of the HEK293T cultures was 
harvested and used to infect the SUM149 cells.  After three rounds of viral 
infection, transduced SUM149 cells were grown in media containing 1 µg/ml 
puromycin to selectively kill any non-infected cells.  A one µg/ml concentration of 
puromycin for selection of SUM149 cells post-lentiviral transduction has been 
previously reported (Baillo et al., 2011).  To confirm that the 1 µg/ml puromycin 
concentration was appropriate for selection in our hands, we monitored the 
growth of SUM149 cells in puromycin concentrations ranging from 0 – 5 µg/ml.  
Within 4 days, the 1 µg/ml concentration killed 100% of the cells, verifying that 
this concentration was appropriate for selection of SUM149 cells.  
Concentrations of puromycin below 1 µg/ml did not kill all cells, whereas 
concentrations above 1 µg/ml were toxic within 1 to 2 days.  
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Figure 3.10.  shRNA target gene set for caveolin-1 gene.  (A) Table of the 6 
clone IDs and their respective sense and anti-sense sequences.  (B) The coding 
sequence of the caveolin-1 gene.  The clones are highlighted or underlined 
indicating their target site within the mRNA of caveolin-1.  
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 Of the six constructs tested, two induced the greatest levels of caveolin-1 
knockdown.  To investigate the effect of shRNAmir on the protein expression of 
caveolin-1 in the transduced SUM149 cells, we performed immunoblot analysis 
of cellular lysates of knockdown SUM149 cells ± doxycycline and of the parental 
SUM149 cells (Figure 3.11A).  Immunoblotting showed a large decrease in 
caveolin-1 protein levels in two clones: C8 and F2.  Densitometric analysis of the 
protein bands revealed that when the shRNAmir expression is turned on (i.e., + 
doxycycline), caveolin-1 protein expression was decreased approximately 40% in 
clone C8 and 95% in clone F2 (Figure 3.11B).  As a result of these findings, all 
future experiments were performed with clones C8 and F2 ± doxycycline.  As a 
negative control, we also transduced SUM149 cells with a non-silencing-TRIPZ 
lentiviral shRNAmir control that does not target any mRNA sequence in the 
mammalian genome. 
 
Knockdown of caveolin-1 does not affect morphology of IBC cells.  
As early as 1976, Rohlich and Allison described how the pattern of membrane-
associated vesicles, now known to be caveolae, depended on intact microtubule 
bundles (Rohlich and Allison, 1976).  Later studies demonstrated that the cellular 
distribution and dynamics of caveolae require an intact cytoskeleton (Parton et 
al., 1994) and that actin is detected in caveolae-enriched microdomains  (Lisanti 
et al., 1994; Smart et al., 1995).  Caveolae form a bridge between the 
extracellular matrix and the cytoplasm.  For example, reducing expression of 
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Figure 3.11.  Caveolin-1 knockdown in SUM149 cells.  (A) SUM149 cells 
stably infected with caveolin-1 shRNA lentiviral expression constructs were 
grown on plastic in either the presence or absence of doxycycline. P = parental 
SUM149.  Cell lysate was harvested, separated by 12% SDS-PAGE under 
reducing conditions and transferred to nitrocellulose.  Membranes were blotted 
for antibodies against caveolin-1 and β-tubulin as a loading control. (B) 
Quantification of densitometric analysis of caveolin-1 signal.  Red bar indicates 
the decrease in caveolin-1 protein level for each clone. 
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caveolin-1 by an antisense approach disrupts β-1 integrin signaling leading to 
reduced focal adhesions, phosphorylation of focal adhesion kinase and cell 
adhesion (Wei et al., 1999).  To test the effect of caveolin-1 knockdown on the 
morphology of IBC cells, we cultured control and knockdown populations in 3D 
rBM overlay cultures.  Parental SUM149 cells grown in three-dimensional rBM 
overlay cultures form spheroid-like multicellular structures (Mohamed et al., 
2008).  Here, a single cell suspension of 25,000 transduced SUM149 cells was 
seeded onto round glass coverslips coated with solidified rBM.  The cells were 
allowed to adhere to the rBM for 45 minutes.  Growth medium containing 2% rBM 
was then overlaid onto the cultures.  After 48 hours in culture we assessed 
morphology, in 3 independent experiments by confocal microscopy by examining 
a tile of 12 fields of vew of cells grown in 3D.  With regard to structure complexity 
an shape, there were no obvious differences of the 3D structures when control 
shRNAmir cells and knockdown clones were cultured in either the presence or 
absence of doxycycline (Figure 3.12).  These data suggest that the absence of 
caveolin-1 does not affect the morphology of IBC cells. 
 
Caveolin-1 knockdown does not affect proliferation of SUM149 cells.  
Caveolin-1 negatively regulates cell proliferation.  For example, serum starvation 
of NIH 3T3 cells increases endogenous levels of caveolin-1 expression and 
induces cell cycle arrest in the G0/G1 phase (Galbiati et al., 2001).  In addition to 
these findings, mouse embryonic fibroblasts isolated from caveolin-1 transgenic
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Figure 3.12. Comparitive growth and morphology of 3D rBM cultures of 
caveolin-1 knockdown SUM149 cells.  SUM149 cells stably infected with 
caveolin-1 shRNA lentiviral expression constructs were grown in 3D rBM culture 
either the presence or absence of doxycycline.  Cultrex coated glass coverslips 
were seeded with 25,000 cells and grown for 2 days. Merged DIC and 
fluorescent tile images of the cultures were imaged using confocal microscopy.  
Magnification, 40X. 
	  	  
68 
mice exhibit a p53/p21-mediated reduction in cellular proliferation.  A growth 
regulating function of caveolin-1 has also been demonstrated in a panel of non-
IBC human breast cancer cell lines (Lee et al., 1998).  To evaluate whether 
knockdown of caveolin-1 affects proliferation of IBC cells, we performed MTT 
assays over a 72 h period.  Cultures of control shRNAmir cells, clones C8 and F2 
were grown in the presence of 500 ng/ml of doxycycline or absence.  
Interestingly knockdown of caveolin-1 expression did not change the proliferation 
of IBC cells as measured by the ability of cells to reduce the MTT substrate  
(Figure 3.13). 
 
Knockdown SUM149 cells exhibit altered distribution of caveolin-1.  
Analysis of whole cell lysates demonstrated that shRNAmir sequences resulted 
in decreased caveolin-1 protein (Figure 3.11).  In addition we analyzed the 
subcellular localization of caveolin-1 in both control and knockdown populations.  
Transduced SUM149 cells were grown in the absence or presence of 
doxycycline to induce expression of the shRNAmir.  These cultures were then 
subjected to the detergent-based method of subcellular fractionation separating 
Triton X-100-soluble (TS) from –insoluble (TI) membrane components.  Equal 
volume aliquots of each fraction were separated by 12% SDS-PAGE under 
reducing conditions, transferred to nitrocellulose and probed for caveolin-1.  In 
comparison to untreated samples (no doxycycline), caveolin-1 protein levels 
were clearly reduced in both fractions of clones C8 and F2 treated with
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Figure 3.13.  Knockdown of caveolin-1 does not alter proliferation of IBC 
cells as assessed by MTT assays.  Control shRNAmir, clone C8 and clone F2 
were seeded in 96-well plates (5,000 per well) ± doxycycline.  At 24, 48 and 72 h 
time points, 50 µl of MTT stock solution was added to each well and incubated at 
37°C for 3 hours.  Media was removed and 150 µl of DMSO added to each well 
dissolving the formazan precipitate.  Absorbance values were measured at a 
485-nm wavelength. 
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doxycycline (Figure 3.14).  As expected, no discernable difference was observed 
in the control shRNAmir cells ± doxycycline. 
 
Knockdown of caveolin-1 decreases degradation of DQ-collagen IV 
by SUM149 3D cultures.  We have previously shown that caveolin-1 expression 
affects the degradation of collagen type IV (Cavallo-Medved et al., 2005).  When 
antisense was used as a method to target caveolin-1 expression in human 
colorectal carcinoma cells, they degraded less collagen IV than control cells.  
Therefore, we investigated whether downregulation of caveolin-1 can affect the 
ability of IBC cells to degrade type IV collagen.  Using our live-cell proteolysis 
assay we demonstrated that cleavage products of type IV collagen were found 
adjacent to the external cell surface of parental SUM149 cells (Figure 3.2).  We 
seeded individual cells of knockdown populations and control shRNAmir cells 
onto rBM containing DQ-collagen IV and grew them for 48 hours ± 500 ng/ml 
doxycycline.  We then imaged DQ-collagen IV degradation in live cultures of IBC 
cells using confocal microscopy.  Both caveolin-1 knockdown and control 
shRNAmir cells exhibited a pericellular pattern of proteolysis similar to that of the 
parental SUM149 cells.  Confocal Z stack images were captured throughout the 
three-dimensional volume and used to generate 3D reconstructions (Figures 
3.15-3.17).  Quantitative analysis with Metamorph software revealed that control 
shRNAmir cells and clone C8 cultures exhibited no significant difference in the 
intensity of degradation products ± doxycycline treatment (Figure 3.18).  
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Figure 3.14. Distribution of caveolin-1 to lipid enriched fractions is 
decreased in knockdown SUM149 cells.  Caveolae-enriched fractions from 
transduced SUM149 grown ± 500 ng/ml doxycycline were isolated by a 
detergent-based method that separates Triton X-100-soluble (TS) from Triton X-
100–insoluble (TI) cellular fractions. Equal volumes of each fraction were 
analyzed by SDS-PAGE and immunoblotted with antibodies against caveolin-1.   
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Figure 3.15. Degradation of DQ-collagen IV by control shRNAmir cells.  
Control shRNA mir cells were grown as 3D cultures in rBM containing DQ-
collagen IV in the presence (+ dox) or absence (- dox) of 500 ng/ml doxycycline.  
Representative 3D reconstructions of DQ-collagen IV degradation products 
(green) and corresponding DIC images shown.  Magnification, 40X. 
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Figure 3.16. Degradation of DQ-collagen IV by caveolin knockdown cells.  
Clone C8 cells were grown as 3D cultures in rBM containing DQ-collagen IV in 
the presence (+ dox) or absence (- dox) of 500 ng/ml doxycycline.  
Representative 3D reconstructions of DQ-collagen IV degradation products 
(green) and corresponding DIC images shown.  Magnification, 40X. 
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Figure 3.17. Degradation of DQ-collagen IV by caveolin knockdown cells.  
Clone F2 cells were grown as 3D cultures in rBM containing DQ-collagen IV in 
the presence (+ dox) or absence (- dox) of 500 ng/ml doxycycline.  
Representative 3D reconstructions of DQ-collagen IV degradation products 
(green) and corresponding DIC images shown.  Magnification, 40X.  Bar, 50 µm. 
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In contrast, a significant reduction in degradation of DQ-collagen IV by clone F2 
cells was observed.  Thus, in the F2 clone cells, when expression of the 
caveolin-1 targeting shRNAmir is induced, i.e. + doxycycline, and expression of 
caveolin-1 is knocked down, degradation by IBC cells of collagen IV is reduced.  
 
Caveolin-1 knockdown results in reduced invasion by IBC cells.  An 
abundance of tumor emboli in lymphatic vessels is one pathological feature 
distinguishing IBC from non-IBC (Bonnier et al., 1995).  Therefore, we studied 
the role of caveolin-1 in the invasive phenotype of IBC.  Invasion through 
transwell filters coated with rBM is a commonly used assay to test the invasive 
capacity of cells in vitro.  In these experiments, we seeded equal numbers of 
control shRNAmir, clone C8 or clone F2 cells on rBM-coated transwell filters with 
or without 500 ng/ml of doxycycline.  The cells were incubated with serum free 
media and complete media (Ham’s F12 media with 5% FBS) below the rBM-
coated transwell filter to stimulate invasion.  Following 24 hours rBM and non-
invasive cells were removed from the top of filter.  The cells that had invaded, 
i.e., the cells attached to the bottom of the filter insert, were fixed and stained 
using Diff-Quik Stain Set.  Filters were cut from the insert, mounted on a slide 
and invaded cells were imaged for counting by two independent observers.  Only 
the clone F2 exhibited a decrease in the number of invaded cells when treated 
with 500 ng/ml doxycycline relative to untreated (Figure 3.19). 
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Figure 3.18. Knockdown of caveolin-1 decreases degradation of DQ-
collagen IV by IBC cells. Quantification of proteolysis in the entire volume of 
three-dimensional structures measured as the average integrated intensity of 
fluorescence was normalized to the number of cells. Results from at least three 
independent experiments are presented as mean ± SD; *, P< 0.05. 
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Figure 3.19.  Knockdown of caveolin-1 expression decreases the 
invasiveness of IBC cells.  Transduced SUM149 cells were subjected to 
transwell invasion assays in the presence of 500 ng/ml of  doxycycline (+ dox) or 
untreated (- dox). (A) Images are cells that have invaded through rBM-coated 
filters.  Magnification, 20X. (B) Quantification of invaded cells was performed by 
counting the number of cells that invaded through rBM-coated transwell filters.  
Bars represent mean ± SD; n=3. 
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Cathepsin B distributes to lipid microdomains in caveolin-1 
knockdown IBC cells.  Active cathepsin B localized to caveolae-enriched 
microdomains of SUM149 parental cells (Figure 3.4).  We also demonstrated that 
inhibition of pericellular cathepsin B activity reduced extracellular matrix 
degradation and invasion of SUM149 parental cells (Figures 3.6 and 3.7).  
Caveolin-1 knockdown studies (Figures 3.15-17) revealed similar decreases in 
degradation and invasion by the F2 clone.  To determine if caveolin-1 mediates 
cell surface localization of cathepsin B, we examined the subcellular distribution 
of cathepsin B in control shRNAmir cells and caveolin-1 knockdown populations.  
Three-dimensional rBM overlay cultures of control shRNAmir cells and caveolin-1 
knockdown cells ± 500 ng/ml of doxycycline were subjected to detergent-based 
subcellular fractionation.  Interestingly, we observed no change in the distribution 
of cathepsin B in caveolin-1 knockdown (doxycycline treated) cells as compared 
to untreated cells (Figure 3.20A).  As expected, no changes in the distribution of 
cathepsin B were observed in control shRNAmir transduced cells ± doxycycline 
treatment (Figure 3.20A).  The TS and TI fractions of control shRNAmir and 
clone F2 were also assayed for cathepsin B activity.  We detected no differences 
in the activity of cathepsin B in doxycycline treated caveolin-1 knockdown (Figure 
3.20C) and control shRNAmir cells (Figure 3.20B).  These findings correspond to 
those of our immunoblotting studies and suggest that decreased caveolin-1 in the 
TI fraction and more specifically in the lipid microdomain fractions of IBC cells 
has no effect on the subcellular distribution of cathepsin B.  We also investigated 
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Figure 3.20.  Active cathepsin B is present in caveolae-enriched fractions of 
caveolin-1 knockdown SUM149 cells in 3D cultures.  Control shRNAmir and 
clone F2 3D cultures were subjected to detergent-based cellular fractionation 
method, as described in Materials and Methods, that separate Triton X-100-
soluble (TS; non-caveolae) from Triton X-100–insoluble (TI; caveolae-enriched) 
cellular fractions.  (A) Equal volume aliquots of each fraction were analyzed by 
SDS-PAGE and immunoblotted with antibodies against cathepsin B and 
caveolin-1.  (B) Equal volume aliquots of (B) control mir and (C) clone F2 TS and 
TI fractions were assayed for enzymatic activity against the synthetic cathepsin B 
substrate Z-Arg-Arg-NHMec. 
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the localization of uPA and other proteins known to be associated with caveolae.  
In human colorectal carcinoma cells, we have established that the cell surface 
association of cathepsin B, uPA and their binding partners is caveolin-1 
dependent (Cavallo-Medved et al., 2005).  We observed no changes in the 
distribution to TI fractions of uPA, E-cadherin, β1-integrin, p36 and p11 in control 
shRNAmir cells when treated with doxycycline as compared to untreated cells 
(Figure 3.21).   In contrast, knockdown caveolin-1 cells exhibited decreased 
distribution of uPA to the TI fraction when treated with doxycycline as compared 
to untreated cells (Figure 3.22).   
 Inhibiting cathepsin B activity reduced both type IV collagen degradation 
and invasion by IBC cells.  Downregulation of caveolin-1 in IBC cells did not 
change the distribution of cathepsin B at the cell surface.  Knockdown of 
caveolin-1 in clone F2 cells did, however, cause a decrease in both the 
degradation of collagen IV and invasion, consistent with a mechanism other than 
cathepsin B activity may be responsible for these findings.  Signaling pathways 
mediated by EGFR have been thoroughly studied especially in TNBC [for review, 
see (Foley et al., 2010)].  Overexpression of EGFR and caveolin-1 are 
associated with triple negative breast cancers (Pinilla et al., 2006; Rastelli et al., 
2010).  This includes SUM149, a triple negative breast cancer cell line that also 
expresses EGFR, and in which EGFR localizes to lipid microdomains (Irwin et 
al., 2011).  To determine if caveolin-1 mediates the association of EGFR with 
lipid microdomains, we assessed the subcellular distribution of EGFR in caveolin- 
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Figure 3.21.  Subcellular distribution of E-cadherin, β1-integrin, uPA, p36 
and p11 is unchanged in control shRNAmir transduced IBC cells.  Caveolae 
enriched fractions were isolated from control shRNAmir cells ± doxycycline by a 
detergent based method that separates Triton X-100-soluble (TS) from –
insoluble (TI) membrane components.  TS indicates non-caveolae fractions and 
TI indicates caveolae-enriched fractions.  Equal volumes of each fraction were 
analyzed by SDS-PAGE and immunoblotted with anti-E-cadherin, anti-β1-
integrin, anti-uPA, anti-p36, anti-p11 and anti-transferrin receptor (TfR) 
antibodies.  TfR is a negative control for lipid rafts. 
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Figure 3.22.  E-cadherin, β1-integrin, uPA, p36 and p11 are present in 
caveolae-enriched fractions of caveolin-1 knockdown SUM149 cells in 3D 
culture.  Caveolae enriched fractions were isolated from clone F2 ± doxycycline 
by a detergent based method that separates Triton X-100-soluble (TS) from –
insoluble (TI) membrane components.  TS indicates non-caveolae fractions and 
TI indicates caveolae-enriched fractions. Equal volumes of each fraction were 
analyzed by SDS-PAGE and immunoblotted with anti-E-cadherin, anti-β1-
integrin, anti-uPA, anti-p36, anti-p11 and anti-transferrin receptor (TfR) 
antibodies.  TfR is a negative control as it is not associated with lipid rafts. 
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1 knockdown cells.  We observed decreased EGFR in both TS and TI fractions of 
clone F2 cells when treated with 500 ng/ml doxycycline (Figure 3.23).  These 
findings indicate that caveolin-1 may play a role in the expression of EGFR and 
mediate its cell surface localization in IBC cells. 
 
Analysis of caveolin-1 expression and cathepsin B localization in a 
new IBC cell line.  The human cell line MDA-IBC-3 (a kind gift of Dr. Wendy 
Woodward developed at The University of Texas MD Anderson Cancer Center, 
Texas) was obtained from a patient with IBC and generated from primary breast 
cancer cells isolated from pleural effusion fluid (Klopp et al., 2010).  The SUM149 
and SUM190 are the only commercially available IBC cell lines for in vitro 
investigation.  Therefore, we thought it important to test our hypothesis with this 
additional IBC cell line.  To initiate analysis of the new IBC cell line, we compared 
the protein expression of cathepsin B and caveolin-1 in three IBC cell lines 
(SUM149, SUM190 and MDA-IBC-3) when grown in monolayer cultures on 
plastic.  MDA-IBC-3 cells express more cathepsin B protein as assessed by 
SDS-PAGE and immunoblotting (Figure 3.24A).  We previously found that 
SUM190 does not have detectable caveolin-1 protein and surprisingly neither 
does the MDA-IBC-3 cell line (Figure 3.24A). 
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Figure 3.23. Knockdown of caveolin-1 decreases the expression and cell 
surface localization of EGFR in IBC cells.  Control mir and clone F2 3D 
cultures were subjected to detergent-based cellular fractionation method, as 
described in Materials and Methods, that separate Triton X-100-soluble (TS; non-
caveolae) from Triton X-100–insoluble (TI; caveolae-enriched) cellular fractions.  
(A) Equal volume aliquots of each fraction were analyzed by SDS-PAGE and 
immunoblotted with antibodies against EGFR. 
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Figure 3.24.  Cathepsin B expression and localization in a new IBC cell line 
MDA-IBC-3.  (A) IBC cells (SUM149, MDA-IBC-3 and SUM190) grown on plastic 
were harvested in lysis buffer (10 mM Tris, pH 7.5, 50 mM NaCl, 1% Triton X-
100, 60 mM octylglucoside) and equally loaded samples separated by 12% SDS-
PAGE under reducing conditions.  Proteins were transferred to nitrocellulose 
membrane and immunoblotted with anti-CTSB and anti-caveolin-1 polyclonal 
antibodies.  The immunoblot for caveolin-1 was overexposed to ensure no 
observable caveolin-1 signal was detectable in MDA-IBC-3 and SUM190 lysate.  
(B) MDA-IBC-3 cells grown as a monolayer were subjected to subcellular 
fractionation on a sucrose gradient.  Equal volumes of each fraction were 
analyzed by SDS-PAGE and immunoblotted for cathepsin B.  
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Cathepsin B localizes to plasma membrane domains other than 
caveolae. Caveolin-1 protein expression is essential to caveolae formation (Drab 
et al., 2001; Razani et al., 2001).  Since caveolin-1 protein was not detected in 
both MDA-IBC-3 and SUM190 lysates, we hypothesized that these cells might 
not have caveolae. Subcellular fractionation of SUM190 cells showed that 
cathepsin B localized to low-density lipid fractions despite the absence of 
caveolin-1 (Cavallo-Medved, unpublished data).  We also investigated the 
subcellular localization of cathepsin B in MDA-IBC-3 cells.  We subjected MDA-
IBC-3 cells grown in monolayer to the non-detergent based sucrose density 
fractionation gradient method.  As expected cathepsin B localized to fractions 8-
11, i.e., fractions containing endolysosomes (Figure 3.24B).  Cathepsin B also 
distributed to a low-density lipid fraction, i.e., fraction 5, containing lipid 
microdomains.  These data suggest that cathepsin B may localize to non-
caveolar lipid microdomains in the plasma membrane of MDA-IBC-3 cells. 
 
Treatment of IBC cells with lovastatin: a pharmacological approach 
to disrupt lipid microdomains.  Statins are a class of drug primarily used in 
prevention, monitoring and treatment of cardiovascular disease.  Statins prevent 
the catalysis of mevalonate by inhibiting the enzymatic activity of HMG-CoA 
reductase, an important rate-limiting step in the cholesterol biosynthesis 
pathway.  Therefore, statins have lipid-lowering activity.  Asymmetric distribution 
of cholesterol and other lipids in the plasma membrane results in lipid-enriched 
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domains or lipid rafts including caveolae (Simons and Ikonen, 1997; Simons and 
Toomre, 2000).  Caveolae are a specialized and distinct type of lipid raft, which 
are highly enriched in and dependent on cholesterol for biosynthesis (Rothberg 
et al., 1992).  We hypothesize that cholesterol depletion by statin drugs will 
disrupt lipid microdomains, including caveolae.  Here we used a statin, lovastatin, 
as an alternative approach for testing our hypothesis that cell surface association 
of the cysteine protease cathepsin B, the serine proteases of the plasminogen 
cascade in caveolae enhances cell surface proteolysis, and ultimately, the 
aggressiveness of IBC cells. 
 
Proliferation of IBC cell lines differs in response to lovastatin 
treatment.  Statins have been reported to reduce proliferation of breast cancer 
cells in vitro and in vivo (Campbell et al., 2006).  In the study by Campbell et al., 
treatment with multiple statins, including lovastatin, inhibited growth of MDA-231, 
SKBr3 and MCF-7 cells.  To determine the effects of lovastatin on growth of IBC 
cells, we performed MTT assays.  Proliferation of SUM149, SUM190 and MDA-
IBC-3 cells was quantified at 0, 24, 48 and 72 hours in the presence of 3 µM 
lovastatin or DMSO (vehicle control) (Figure 3.25).  We observed no change in 
the proliferation of SUM190 cells at any time point (Figure 3.25B).  A small, but 
insignificant, decrease in proliferation of SUM149 cells was observed, but only 
after treatment for 72 hours (Figure 3.25A).  MDA-IBC-3 cells were most 
sensitive to lovastatin in that proliferation was significantly decreased beginning
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Figure 3.25.  Lovastatin decreases proliferation of MDA-IBC-3 cells.  (A) 
SUM149, (B) SUM190, and (C) MDA-IBC-3 cells were seeded in 96-well plates 
(5,000 per well) with 3 µM lovastatin or DMSO (vehicle control).  At 0, 24, 48 and 
72 h time points, 50 µl of MTT stock solution was added to each well and 
incubated at 37°C for 3 hours.  Media was removed and 150 µl of DMSO added 
to each well dissolving the formazan precipitate.  Absorbance values were 
measured at a 485-nm wavelength with a SpectraFluor Plus plate reader (Tecan, 
Salzburg, Austria).  Results from three independent experiments are presented 
as mean ± SD. 
	  	  
91 
48 hours after drug treatment (Figure 3.25C).  These results indicate that the 
three IBC cells do not exhibit the same pattern of lovastatin responsiveness. 
 
Lovastatin treatment of IBC cells decreases cathepsin B expression 
and activity.  In models of cardiac hypertrophy and atherosclerosis, statin 
treatment has been shown to inhibit the expression and activity of proteases, 
including cathepsin B (Kim et al., 2009; Qin et al., 2010).  We investigated the 
expression of cathepsin B protein in IBC cells following treatment with lovastatin.  
At 48, 72 and 96 hours, lysate samples were collected and assayed by SDS-
PAGE and immunoblotting.  We observed no changes in expression of cathepsin 
B in the presence of 1 µM lovastatin at any time point (data not shown).  Three 
µM lovastatin did decrease levels of cathepsin B protein (Figure 3.26A).  This 
effect of lovastatin treatment was not time-dependent as further decreases did 
not occur at 72 and 96 h, as assessed by densitometric analysis of immunoblots 
(data not shown).  The differences in cathepsin B were most striking at the 48 
hour time point (Figure 3.26B).  We also measured intracellular cathepsin B 
activity in the lysates of lovastatin treated SUM149 cells.  In agreement with the 
decreases in the mature (31 and 25/26 kDa) cathepsin B forms observed by 
immunoblotting, cathepsin B activity was reduced by treatment with lovastatin 
(Figure 3.26C).  These findings were not exclusive to SUM149 cells; exposure to 
3 µM lovastatin for 48 h reduced cathepsin B activity and protein levels in MDA-
IBC-3 and modestly in SUM190 (Figure 3.27A-C) cells.  The effect of lovastatin
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Figure 3.26.  Lovastatin treatment decreased cathepsin B expression and 
activity in SUM149 cells.  2D cultures of SUM149 were grown in the presence 
of 3 µM lovastatin for 48, 72 or 96 hours.  (A) Lysates were equally loaded based 
on protein concentration and separated on 12% SDS-PAGE under reducing 
conditions.  Proteins were transferred to nitrocellulose and immunoblotted with 
an anti-cathepsin B polyclonal antibody and anti-β-tubulin monoclonal antibody 
as a loading control. (B) Densitometric analysis (48 h exposure to lovastatin) of 
cathepsin B signal for the different molecular weight species of cathepsin B 
(expressed as AU/mm2).  Proform, 45 kDa; intermediate 38 kDa, single chain 
mature, 31 kDa; double chain mature, 25/26 kDa. (C) Enzymatic activity assay.  
Lovastatin treated and control SUM149 (48 hours) lysate samples were assayed 
for cathepsin B activity against the synthetic substrate Z-Arg-Arg-NHMec.  Error 
bars represent standard deviation of three replicates in one experiment.  
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Figure 3.27.  Lovastatin treatment decreased cathepsin B expression and 
activity in IBC cells.  2D cultures of MDA-IBC-3 and SUM149 cells were grown 
in the presence of 3 µM lovastatin for 48 hours. (A) Lysates were equally loaded 
based on protein concentration and samples were separated on 12% SDS-PAGE 
under reducing conditions.  Proteins were transferred to nitrocellulose and 
immunoblotted with an anti-cathepsin B polyclonal antibody and anti-β-tubulin 
monoclonal antibody as a loading control. (B) MDA-IBC-3 and (C) SUM190 
lysate samples were assayed for cathepsin B activity against the synthetic 
substrate Z-Arg-Arg-NHMec.  Error bars represent standard deviation of three 
replicates in one experiment. 
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on cathepsin B protein and activity seems a general phenomenon since we 
observed similar results in three unrelated IBC cell lines.   
Statins have shown promise in inhibiting fibrosis (Trebicka et al., 2010); 
proteases of the plasminogen cascade, including uPA, play a principal role in 
fibrinolysis. We also investigated if statin treatment can affect expression of uPA.  
Treatment with lovastatin reduced the amount of both secreted and intracellular 
uPA in SUM149 cells but no change was observed in its receptor uPAR (Figure 
3.28).   
 
Treatment with lovastatin decreases cholesterol in IBC cells.  The 
fluorescent antifungal filipin has a high affinity for cholesterol or sterol molecules 
that contain a 3β-hydroxyl group and is commonly used to detect non-esterified 
cholesterol/sterols (Gimpl and Gehrig-Burger, 2007).  Due to this property, filipin 
is widely used as a histochemical stain for cholesterol, e.g., filipin staining of 
cholesterol in cellular membranes is used as a diagnostic tool for Niemann-Pick 
disease (Ledvinova and Elleder, 1993).  To further investigate the lipid lowering 
activity of lovastatin in IBC cells, SUM149 cells treated with 3 µM lovastatin or 
DMSO for 48 hours were fixed and stained with filipin III.  In comparison to 
control cells, we observed decreased staining intensity for filipin III along the 
periphery of cells treated with lovastatin (Figure 3.29), indicative of decreases in 
total cellular cholesterol.  These data provide an indirect indication that treatment  
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Figure 3.28.  Lovastatin treatment decreases expression and secretion of 
uPA in SUM149 cells.  Cell lysate (intracellular) and conditioned media 
(secreted) samples from 2D cultures of  SUM149 treated with 3 µM lovastatin for 
48 hours were separated on 12% SDS-PAGE under reducing conditions. 
Proteins were transferred to nitrocellulose and immunoblotted with an anti-uPA 
antibody, anti-uPAR and an anti-β-tubulin monoclonal antibody as a loading 
control. 
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Figure 3.29.  Lovastatin decreases cholesterol content in SUM149 cells.  (A) 
Representative fluorescent images of SUM149 treated with 3 µM lovastatin or 
DMSO (vehicle control) for 48 hours and stained with filipin III. (B)Intensity of 
filipin III staining of SUM149 cells was analyzed with Metamorph software and 
represented as arbitrary intensity values (n=20). 
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with lovastatin decreased cholesterol in IBC cells and thereby affected lipid 
microdomains, including caveolae. 
 
Lovastatin affects caveolin-1 levels in lipid-enriched fractions of 
SUM149 cells. Treatment with simvastatin, another member of the statin class of 
pharmaceuticals, decreases both cholesterol content and caveolin-1 expression 
in lipid fractions of human glioma cells (Wu et al., 2009).  To determine if 
lovastatin elicits a similar effect on caveolin-1 in IBC cells, SUM149 cells were 
treated with lovastatin for 48 hours and subjected to subcellular fractionation on a 
sucrose gradient.  Caveolin-1 primarily distributed to fractions 4-6 in control 
(DMSO) cells (Figure 3.30A) in agreement with previous data (Figure 3.3).  We 
observed a decrease in the distribution of caveolin-1 to these lipid fractions when 
SUM149 cells were treated with lovastatin (Figure 3.30A).  We also isolated 
caveolae-enriched fractions by a successive detergent based method: TS 
represents non-caveolae fractions and TI represents caveolae-enriched fractions.  
In the presence of lovastatin we observed decreased caveolin-1 in the TI fraction 
and a moderate increase in the TS fraction.  This would be consistent with a 
change in localization of caveolin-1.  In agreement with these data, we observed 
decreases in caveolin-1 localization when SUM149 were cells treated with 
lovastatin.  The staining pattern for caveolin-1 in DMSO (diluent control) treated 
cells is along the plasma membrane.  Following treatment with lovastatin,
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Figure 3.30.  Lovastatin decreased caveolin-1 distribution to lipid fractions 
of IBC cells. SUM149 cells treated with 3 µM lovastatin or DMSO (vehicle 
control) for 48 hours were subjected to both non-detergent sucrose gradient (A) 
and detergent based (C) subcellular fractionations.  Equal volumes of each 
fraction were analyzed by SDS-PAGE and immnoblotted for caveolin-1.  (B) 
Protein bands were analyzed by densitometry.  Graphical representation of 
caveolin-1 distribution in the sucrose gradient fractions. 
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Figure 3.31.  Immunostaining of lovastatin treated SUM149 reveals a 
decrease in caveolin-1 along the cell periphery.  Immunostaining for caveolin-
1 (green) was performed on permeabilized SUM149 monolayer cultures treated 
with 3 µM lovastatin or DMSO (vehicle control).  Nuclei were stained with DAPI 
(blue).  Confocal images were captured using a Leica TCS SP5 confocal 
microscope and 63X oil objective.  Bar, 25 µm.  
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caveolin-1 staining exhibits a more cytoplasmic pattern with less staining at the 
plasma membrane (Figure 3.31). 
 
Mevalonic Acid (MVA) rescues changes in cathepsin B subcellular 
distribution and decreases in cathepsin B activity in lovastatin treated IBC 
cells.  Our knockdown studies revealed that cathepsin B membrane association 
is independent of caveolin-1 expression.  However, lovastatin decreased 
cathepsin B protein levels, cholesterol content and caveolin-1 association with 
lipid fractions of IBC cells.  To determine whether lovastatin affects the 
subcellular distribution of cathepsin B, 3D cultures of IBC cells were treated for 
48 hours with 3 µM of drug and subjected to subcellular fractionation using the 
detergent based method.  We also treated the cultures with MVA in the presence 
of lovastatin.  HMG-CoA reductase, the direct target of statin drugs, catalyzes 
production of MVA in the cholesterol biosynthesis pathway.  Therefore, we added 
exogenous MVA to test if this would rescue the lovastatin-induced phenotype.  In 
agreement with the data in figure 3.4, cathepsin B was present in both the TS 
and TI fractions of SUM149 control (DMSO) cultures (Figure 3.32A).  Treatment 
with lovastatin decreased the amount of cathepsin B in both the TS and TI 
fractions.  MVA partially rescued the observed decreases (Figure 3.32A).  We 
also performed this experiment of MDA-IBC-3 and SUM190 IBC cells.  Similar to 
our findings in the SUM149 cultures, cathepsin B protein levels were decreased 
in both TS and TI fractions of MDA-IBC-3 cells when treated with lovastatin and
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Figure 3.32.  Mevalonic acid (MVA) partially rescues lovastatin-induced reduction 
of cathepsin B protein and activity in subcellular fractions of SUM149 3D cultures.  
SUM149 3D cultures were isolated by a detergent-based method, as described in 
Materials and Methods, that separate Triton X-100-soluble (TS) from Triton X-100–
insoluble (TI) cellular fractions. (A) Equal volume aliquots of each fraction were analyzed 
by SDS-PAGE and immunoblotted with an antibody against cathepsin B.  (B) TS and TI 
fractions were assayed for enzymatic activity against the synthetic cathepsin B substrate 
Z-Arg-Arg-NHMec.  Cathepsin B activity in both TS and TI fractions was inhibited by 3 
µM Lovastatin.  MVA rescued this phenotype. 
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Figure 3.33.  Mevalonate (MVA) partially rescues lovastatin-induced 
reduction of cathepsin B protein and activity in subcellular fractions of 
MDA-IBC-3 3D cultures.  MDA-IBC-3 3D cultures were isolated by a detergent-
based method, as described in Materials and Methods, that separate Triton X-
100-soluble (TS) from Triton X-100–insoluble (TI) cellular fractions.  (A) Equal 
volume aliquots of each fraction were analyzed by SDS-PAGE and 
immunoblotted with an antibody against cathepsin B.  (B) TS and TI fractions 
were assayed for enzymatic activity against the synthetic cathepsin B substrate 
Z-Arg-Arg-NHMec.  Cathepsin B activity in both TS and TI fractions was inhibited 
by 3 µM Lovastatin.  MVA partially rescued this phenotype. 
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Figure 3.34. Lovastatin does not affect cathepsin B protein and activity in 
subcellular fractions of SUM190 3D cultures.  SUM90 3D cultures were 
isolated by a detergent-based method, as described in Materials and Methods, 
that separate Triton X-100-soluble (TS) from Triton X-100–insoluble (TI) cellular 
fractions.  (A) Equal volume aliquots of each fraction were analyzed by SDS-
PAGE and immunoblotted with an antibody against cathepsin B.  (B) TS and TI 
fractions were assayed for enzymatic activity against the synthetic cathepsin B 
substrate Z-Arg-Arg-NHMec.  Cathepsin B activity in both TS and TI fractions 
was inhibited by 3 µM Lovastatin. 
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were modestly rescued by adding back exogenous MVA (Figure 3.33A).  The 
SUM190 cells exhibited decreased sensitivity to lovastatin treatment in 
comparison to SUM149 and MDA-IBC-3 cells.  Lovastatin treatment of SUM190 
did not elicit the same decreases in cathepsin B protein levels or changes in 
subcellular distribution (Figure 3.34A). 
Alterations in distribution of cathepsin B were further investigated by 
comparing the activity of cathepsin B in both TS and TI fractions of control, 
lovastatin treated cells and by adding MVA.  We detected cathepsin B activity in 
both the TS and TI control fractions of all three IBC cell lines that were 
comparable to the levels of mature cathepsin B detected by immunoblotting 
(Figures 3.33B, 3.34B and 3.35B).  Treatment with lovastatin reduced the activity 
of cathepsin B in both fractions of SUM149 and MDA-IBC-3 cultures but not in 
the SUM190 cells (Figure 3.34B).  Addition of exogenous MVA in the presence of 
lovastatin partially restored the activity of cathepsin B in both the TS and TI 
fractions of SUM149 and MDA-IBC-3 cultures (Figures 3.32B and 33.3B). 
 
 Lovastatin treatment reduces type IV collagen degradation and 
invasion by IBC cells.  Our subcellular fractionation and enzymatic assays 
indicated that active cathepsin B is associated with TI fractions of IBC cells.  
Lovastatin treatment diminished the levels of cathepsin B protein and activity in 
TI fractions.  In addition, inhibiting cathepsin B activity significantly diminished 
degradation of DQ-collagen IV (Figure 3.6) and invasion (Figure 3.7), suggesting 
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that cathepsin B contributes to pericellular degradation and invasion by IBC cells.  
Therefore, we examined whether treatment with lovastatin would reduce 
degradation of DQ-collagen IV and invasion of IBC cells.  For these studies, we 
used our live cell proteolysis assay to image the degradation of DQ-collagen IV 
by SUM149, MDA-IBC-3 and SUM190 cells grown for 48 hours and treated with 
3 µM lovastatin or DMSO (vehicle control).  Lovastatin significantly decreased the 
intensity of pericellular degradation products of DQ-collagen IV surrounding 
SUM149 3D structures (Figure 3.35A and B). 
 When grown in 3D rBM overlay cultures, MDA-IBC-3 cells form 
spheroid-like multicellular structures similar to those observed for SUM149 cells, 
yet exhibited a different pattern of proteolysis resembling that observed for 
SUM190 cells (Figure 3.2).  The DQ-collagen IV cleavage products associated 
with MDA-IBC-3 structures appeared punctate or intracellular rather than 
pericellular (Figure 3.36).  In addition, we observed the intensity of degradation 
products in MDA-IBC-3 cultures to be less than in SUM149 cultures, indicating 
that these cells degraded less collagen IV.  Similar to the SUM149 cells, 
lovastatin treatment of MDA-IBC-3 cells changed cathepsin B subcellular 
distribution and decreased cathepsin B activity.  When the MDA-IBC-3 cells were 
treated with lovastatin, degradation of DQ-collagen IV was not affected (Figure 
3.36A and B).  Degradation of DQ-collagen IV by SUM190 cells also was not 
affected by treatment with lovastatin (Figure 3.37A and B). 
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Figure 3.35.  Lovastatin reduced degradation of DQ-collagen IV by SUM149 
3D cultures. SUM149 cells grown in 3D rBM cultures containing DQ-collagen IV 
were treated with Lovastatin (3 µM) or DMSO (vehicle control) for 48 hours. (A) 
Representative confocal micrographs of the equatorial plane of the DQ-collagen 
IV degradation channel (green) and corresponding DIC channel are shown.  
Nuclei were stained with Hoechst (blue). Bar, 22 µm. (B) Data are represented as 
integrated fluorescence intensity due to proteolysis in the entire volume of 3D 
structures and was normalized to the number of cells. Results from three 
independent experiments are presented as mean ± SD; *, P<0.008 (Student’s t 
test). 
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Figure 3.36.  Lovastatin did not affect degradation of DQ-collagen IV by 
MDA-IBC-3 3D cultures.  MDA-IBC-3 cells grown in 3D rBM cultures containing 
DQ-collagen IV were treated with Lovastatin (3 µM) or DMSO (vehicle control) for 
48 hours. (A) Representative confocal micrographs of the equatorial plane of the 
DQ-collagen IV degradation channel (green) and corresponding DIC channel are 
shown.  Nuclei were stained with Hoechst (blue).  Bar, 23 µm. (B) Data are 
represented as integrated fluorescence intensity due to proteolysis in the entire  
volume of 3D structures and was normalized to the number of cells. Mean ± SD 
(n=8). 
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Figure 3.37.  Lovastatin did not affect degradation of DQ-collagen IV by 
SUM190 3D cultures.  SUM190 cells grown in 3D rBM cultures containing DQ-
collagen IV were treated with Lovastatin (3 µM) or DMSO (Control) for 48 hours. 
(A) Representative confocal micrographs of the equatorial plane of the DQ-
collagen IV degradation channel (green) and corresponding DIC channel are 
shown.  Nuclei were stained with Hoechst (blue).  Bar, 24 µm. (B) Data are 
represented as integrated fluorescence intensity due to proteolysis in the entire 
volume of 3D structures and was normalized to the number of cells.  Results 
from three independent experiments are presented as mean ± SD. 
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Since lovastatin treatment significantly decreased the degradation of 
collagen IV by SUM149 cells, we also measured the effect the drug may have on 
invasiveness.  For these studies, we performed invasion assays as previously 
described for the caveolin-1 knockdown studies [see page 76]. Briefly, equal 
numbers of SUM149 cells were suspended in serum free media and seeded on 
transwell filters coated with rBM.  Medium containing serum, to stimulate 
invasion, was added to the chamber below the filter.  Cells were incubated with 
lovastatin, lovastatin plus exogenous MVA, or DMSO (vehicle control) for 24 
hours and the number of invaded cells was counted.  Invasion of SUM149 cells 
was significantly reduced by lovastatin (Figure 3.38A and B).  When MVA was 
added in the presence of lovastatin, IBC cells invaded comparably to the vehicle 
controls.  Invasion assays were also performed with the other IBC cell lines; 
however, neither the MDA-IBC-3 or the SUM190 cells invaded under control 
conditions, even up to 5 days following their initial seeding. 
  
Mevalonic Acid (MVA) rescues changes in EGFR subcellular 
distribution in lovastatin treated IBC cells.  Knockdown of caveolin-1 in 
SUM149 cells decreased the localization of EGFR to caveolae-enriched 
subcelluar fractions (Figure 3.23).  Lovastatin treatment also decreased caveolin-
1 association with lipid microdomains of SUM149 cells.  To investigate if 
lovastatin treatment also exerts this same affect on EGFR, we examined the 
subcellular distribution of EGFR in 3D cultures of SUM149 cells.  When treated
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Figure 3.38.  Lovastatin inhibits invasion of SUM149 cells.  SUM149 cells 
were subjected to transwell invasion assays in the presence of DMSO (vehicle 
control), 3 µM Lovastatin or 3 µM Lovastatin + 1 mM MVA.   (A) Images are 
SUM149 cells that have invaded through rBM-coated filters; bar, 150 µm.  (B) 
Quantification of invaded cells was performed by counting the average number of 
invaded cells per filter (using Image J software).  Results from three independent 
experiments are presented as mean ± SD; *, P< 0.001. 
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with lovastatin, less EGFR localized to the TI fraction in comparison to DMSO 
(vehicle control) controls (Figure 3.39).  MVA rescued the observed decreases.     
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Figure 3.39.  Mevalonic acid (MVA) rescues lovastatin-induced reduction of 
EGFR in subcellular fractions of SUM149 3D cultures.  SUM149 3D cultures 
were isolated by a detergent-based method, as described in Materials and 
Methods, that separate Triton X-100-soluble (TS) from Triton X-100–insoluble 
(TI) cellular fractions.  Equal volume aliquots of each fraction were analyzed by 
SDS-PAGE and immunoblotted with antibodies against EGFR and transferrin 
receptor (TfR).  TfR is a negative control for lipid rafts.  MVA rescued this 
phenotype.  
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CHAPTER 4 
 
DISCUSSION 
 
IBC is a rare but highly aggressive form of breast cancer with symptoms 
that develop rapidly (i.e., weeks or months) after initial diagnosis (Vermeulen et 
al., 2009).  Current treatments for IBC are very limited so new therapeutics are 
needed, specifically therapies directed against pathways that mediate the 
aggressive IBC phenotype.  Proteolytic activity is one important mediator of the 
invasion and metastatic spread that are hallmarks of aggressive cancer 
(Hanahan and Weinberg, 2011). Proteases of multiple catalytic classes are 
associated with caveolae, i.e. serine (Stahl and Mueller, 1995), cysteine 
proteases (Cavallo-Medved et al., 2005; Cavallo-Medved et al., 2009) and MMPs 
(Annabi et al., 2001; Puyraimond et al., 2001).  Caveolin-1 is a necessary 
structural and functional component of caveolae.  Caveolin-1 is highly expressed 
in and a potential marker of IBC in vivo (Van den Eynden et al., 2006; Nouh et 
al., 2011). Our approach in this study was to investigate which proteases 
expressed by IBC cells are associated with caveolae, participate in ECM 
degradation and invasion by IBC cells and are present in IBC patient samples.  
Our findings implicate cathepsin B and uPA as contributors to a proteolytic 
pathway that mediates the aggressive IBC phenotype.  Cathepsin B had 
previously been shown to activate pro-uPA, a serine protease and member of the 
plasminogen cascade involved in ECM degradation, matrix metalloproteinase 
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activation and tumor cell invasion (Kobayashi et al., 1991).  In SUM149 cells, 
uPA and its receptor uPAR colocalize with active cathepsin B in caveolae 
(Figures 3.4 and 3.5).  The presence of active cathepsin B in caveolae of IBC 
cells suggests a potential role for this enzyme in pericellular proteolysis as was 
previously shown in colon carcinoma cells (Cavallo-Medved et al., 2005).  
Downregulation of caveolin-1 in the colon carcinoma cells decreases cathepsin B 
localization to caveolae in parallel with decreases in ECM degradation and cell 
invasion (Cavallo-Medved et al., 2005).  In the SUM149 cells used in this study, 
which express both cathepsin B and caveolin-1, we determined that degradation 
of type IV collagen was predominantly pericellular and that a cell impermeant 
cathepsin B inhibitor reduced degradation of type IV collagen and invasion 
(Figures 3.6 and 3.7).  Although significant, the lack of complete inhibition 
suggests that cathepsin B was only one of several proteases in the SUM149 
cells that degrade type IV collagen and mediate invasion.  Others have 
established that cathepsin B interacts with other proteases in mediating invasion.  
For example, Rao and colleagues have demonstrated that downregulation of 
both cathepsin B and uPAR more effectively reduces invasion of human glioma 
cells in vitro and in vivo in an intracranial xenograft model than does 
downregulation of either protease alone.  Furthermore, downregulation of both 
cathepsin B and matrix metalloproteinase 9 (MMP9) reduces invasion of prostate 
tumor cells in vitro and tumor growth in vivo more effectively than downregulation 
of either one of the two proteases (Nalla et al., 2010). These studies confirm that 
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proteases function in concert, and not alone, to facilitate neoplastic progression.  
Proteases can exhibit functional redundancy, including cysteine 
cathepsins (Nagler and Menard, 2003; Mohamed and Sloane, 2006).  A striking 
example occurs between cathepsin B and cathepsin X.  Active cathepsin X is 
redistributed to the surface of MMTV-PyMT mammary tumor cells deficient in 
cathepsin B.  Moreover, cathepsin X neutralizing antibodies reduce invasion of 
the cathepsin B-deficient mammary tumor cells, consistent with cathepsin X 
compensating for the absence of cathepsin B (Vasiljeva et al., 2006). 
The studies above illustrate that observations from in vitro assays such as 
invasion and ECM degradation assays can be meaningful surrogates for in vivo 
tumor endpoints.  In a recent collaborative study (N Withana, BF Sloane and BS 
Parker, unpublished observations), we demonstrated that either knockdown or 
inhibition of cathepsin B in 4T1 mammary carcinoma cells reduced collagen 
degradation in vitro, as assessed by our live-cell proteolysis assay, and bone 
metastasis in vivo.   Here in the three IBC cell lines, we observed differences in 
the degradation of type IV collagen in our live-cell proteolysis assay (Figures 3.2 
and 3.36).  These differences were further supported by variations in expression 
of caveolin-1, cathespin B and uPA, secretion of cathepsin B and uPA and 
expression of known caveolae associated proteins, i.e. uPAR and β1-integrin 
(Figures 3.1 and 3.24).  We propose that these differences may be due, in part, 
to the differences in receptor status of the three IBC cell lines.  Although all three 
lack estrogen and progesterone receptors, only SUM149 is HER2 negative and 
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thus a triple negative breast cancer cell line.  Triple negative breast cancer is a 
subtype of breast cancer characterized as extremely aggressive and having a 
poor prognosis due to difficulties in treating and high risks of both recurrence and 
death (Dawson et al., 2009; Venkitaraman, 2010).  A role for cathepsin B has 
previously been reported in several triple negative breast cancer cell lines that 
are not IBC (e.g., BT20, BT549, MCF-10AneoT, and MDA-MB-231) (Sameni et 
al., 2000; Kos et al., 2005; Gianotti et al., 2008; Gillet et al., 2009); inhibition of 
cathepsin B activity in these cells reduced their invasion in vitro.  In vivo studies 
also provide evidence for an association between cathepsin B and breast 
cancers that are triple negative (Prud'homme et al., 2010) (N Withana, BF Sloane 
and BS Parker, unpublished observations).  In addition, a transgenic mouse 
model of mammary cancer characterized by loss of hormone receptors with 
progression of disease (Maglione et al., 2001) exhibits both reduced primary 
tumor growth and lung metastases when deficient in cathepsin B (Vasiljeva et al., 
2008), suggesting a link between cathepsin B and metastatic breast disease.  
This may be especially true in IBC as expression of cathepsin B was found to be 
positively correlated with lymph node metastasis in IBC tissues, a correlation not 
observed in non-IBC tissues (Nouh et al., 2011).  As such, cathepsin B has been 
proposed to be a prognostic marker for IBC and potentially a component of a 
proposed molecular signature for IBC (Nouh et al., 2011), a signature that 
already includes caveolin-1 (Van den Eynden et al., 2006).  Our current findings 
show that cathepsin B and caveolin-1 were co-expressed in tumor cells of IBC 
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patient samples and not in those of non-IBC patients (Table 3.1).  Ongoing work 
will determine if this co-expression is elevated in non-IBC triple-negative breast 
cancers. 
Another enzyme implicated in the aggressive IBC phenotype is RhoC 
GTPase, which is increased in expression and activity (Kleer et al., 2004; Wu et 
al., 2010).  We speculate that there may be a network that links proteases, 
caveolin-1 and Rho signaling pathways in IBC.  In colon, prostate and non-IBC 
tumors, phosphorylated caveolin-1 has been shown to promote migration and 
invasion via a Rho signaling pathway (Joshi et al., 2008); this has not yet been 
assessed in IBC.  Rho signal transduction pathways have been shown to enrich 
localization of mRNAs to cellular protrusions, pseudopodia, thought to play a role 
in translation of signaling cascades involved in tumor cell migration and 
metastasis (Stuart et al., 2008).  Both cathepsin B and RhoC localize and 
function in podosome or invadopodia mediated tumor cell migration and invasion 
(Tu et al., 2008; MacGrath and Koleske, 2011).  A P132L mutation in caveolin-1 
confers a dominant-negative effect on invasiveness of human scirrhous breast 
cancers (Hayashi et al., 2001) and upregulates genes involved in invasiveness 
and metastasis, including Rho-related signaling molecules and genes expressed 
by stem cells (Bonuccelli et al., 2009).  Studies in MDA-MB-231 breast 
carcinoma cells connect Rho, caveolin-1 and cathepsin B (Bourguignon et al., 
2004).  Rho kinase signaling events, mediated upstream by CD44-NHE1 
interactions localized to lipid microdomains containing caveolin-1, result in 
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acidification of the microenvironment surrounding breast cancer cells, activate 
secretion of cathepsin B and promote cellular invasiveness.  We have previously 
shown that slight acidification of the microenvironment of a variety of tumors 
(melanoma, colon and breast) increases secretion and activity of cathepsin B 
and proteolysis of type IV collagen (Rozhin et al., 1994; Robey et al., 2009; 
Rothberg et al., 2011).  Whether there is a universal link between Rho, caveolin-
1, cathepsin B and acidification of the tumor microenvironment has not yet been 
evaluated. 
One goal of this study was to determine whether cell surface associations 
of proteolytic networks in caveolae enhance the aggressiveness of IBC.  Our 
experimental approach was to downregulate expression of caveolin-1, a 
necessary structural and functional component of caveolae, in IBC cells.  Two of 
the six shRNAmir clones tested, clones C8 and F2, diminished caveolin-1 protein 
levels approximately 40 and 95%, respectively (Figure 3.11B).  Distribution of 
caveolin-1 to lipid enriched fractions was also decreased in knockdown SUM149 
cells (Figure 3.14).  We hypothesize that loss of caveolin-1 expression correlates 
with reduced caveolae biogenesis and thus a loss of caveolae present at the cell 
surface of SUM149 cells.  This conclusion is consistent with previous reports in 
which downregulation of caveolin-1 significantly reduced the number of cell 
surface caveolae (Griffoni et al., 2000; Cho et al., 2003).  We found that 
knockdown of caveolin-1 did not affect the subcellular distribution of cathepsin B.  
These results indicate that cathepsin B localization to lipid microdomains at the 
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cell surface of SUM149 cells is independent of caveolin-1 expression.  This is 
consistent with our findings in the SUM190 and MDA-IBC-3 cell lines, which do 
not express caveolin-1.  Cathepsin B is associated with non-caveolar lipid 
microdomains of both SUM190 cells (Cavallo-Medved, unpublished data) and 
MDA-IBC-3 cells (Figure 3.24).  In contrast, knockdown of caveolin-1 did 
decrease the association of both uPA and EGFR with caveolar lipid 
microdomains.  This suggests that the cell surface associated uPA and EGFR is 
mediated by the expression of caveolin-1 in SUM149 cells and that both proteins 
compartmentalize in caveolae.  The available evidence support that some EGFR 
does localize to caveolae (Smart et al., 1995; Mineo et al., 1996).  That said, 
there is conflict in the literature regarding the quantity of EGFR present in 
caveolae and conditions under which EGFR is found in caveolae [for review, see 
(Balbis and Posner, 2010)].  Caveolin-1 has been shown to function in uPAR-
dependent activation of integrins α5 and β1, Src and EGFR (Monaghan-Benson 
et al., 2008).  Monaghan-Benson and colleagues also report that phosphorylated 
caveolin-1 directs the trafficking of EFGR to focal adhesions. 
Our findings demonstrated that knockdown of caveolin-1 decreased 
degradation of DQ-collagen IV and reduced invasion by SUM149 cells (Figures 
3.18 and 3.19).  This was true for clone F2, in which there was a greater 
reduction of caveolin-1 (cf. Figure 3.11 and Figure 3.14). In other studies, 
threshold levels of caveolin-1 protein expression have been shown to be required 
for the formation of caveolae at the plasma membrane (Fra et al., 1995; Breuza 
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et al., 2002).  Perhaps caveolae biogenesis persists in the clone C8 knockdown 
cells; verification by means of electron microscopy would be necessary to 
validate this hypothesis. 
Caveolin-1 oligomers can form functional plasma membranes domains 
other than caveolae (Head and Insel, 2007).  Caveolin-1 is targeted, in a cell 
specific manner, to other intracellular compartments such as secretory vesicles, 
mitochondria and the cytoplasm (Li et al., 2001).  Caveolin-1 is also a component 
of a cytosolic heat-shock protein chaperone complex functioning in transport of 
cholesterol from the ER to caveolae (Uittenbogaard et al., 1998).  Caveolin-1 
complexes with lipoproteins, is localized to the secretory pathway and secreted 
by pancreatic and exocrine cells (Liu et al., 1999).  In addition, via a scaffolding 
domain of 20 amino acids located in the cytosolic N-terminus region, caveolin-1 
interacts with several signaling molecules including Src tyrosine kinases, G alpha 
subunits, H-Ras, nitric oxide synthase and G-protein-coupled receptors (Li et al., 
1995; Li et al., 1996; Garcia-Cardena et al., 1997).  Indeed, multiple functions 
have been attributed to caveolin-1 that may be independent of caveolae [for 
review, see (Liu et al., 2002a)].  The many other functions of caveolin-1 cannot 
be ruled out as possibly contributing to the aggressiveness of IBC and warrant 
further investigation.  
Our data indicate that the cysteine protease cathepsin B participates in 
degradation of type IV collagen and invasion by IBC cells, likely through its 
association with proteolytic networks in lipid microdomains at the cell surface.  
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Knockdown of caveolin-1 also resulted in decreases in degradation of type IV 
collagen and invasion by IBC cells.  Our original hypothesis was not valid in that 
cathepsin B does not localize specifically to caveolae since downregulating 
caveolin-1 did not affect its association with caveolae.  Therefore we conclude 
that cathepsin B and caveolin-1 both contribute to the aggressiveness of IBC, but 
do so by different mechanisms.   
Statins directly target the activity of HMG-CoA reductase, the rate-limiting 
enzyme in the metabolic pathway that leads to production of cholesterol and 
other isoprenoids.  High blood cholesterol is a risk factor for cardiovascular 
disease, the number one cause of mortality world wide, and statins are important 
in the treatment of this disease (Taylor et al., 2011).  Interestingly, statins are 
associated with pleiotropic beneficial effects including improvement of endothelial 
dysfunction, increased nitric oxide bioavailability, antioxidant and anti-
inflammatory effects (Davignon, 2004).  The multifaceted effects of statins have 
led to investigating their potential use in the prevention and treatment of cancer.  
Long term statin use for five or more years does not reduce the incidence of most 
cancers, including breast cancers (Jacobs et al., 2011).  Nonetheless, in vitro 
and in vivo studies indicate statins may be a useful therapeutic for treatment of 
breast cancer [for review see, (Demierre et al., 2005).  Here as an alternative 
approach to disrupt lipid microdomains, including caveolae, and thereby test our 
hypothesis, we treated IBC cells with a statin drug, lovastatin, to decrease 
cholesterol biosynthesis.  
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Statins have anti-proliferative affects on breast cancer cells in vitro and in 
vivo (Rao et al., 1999; Campbell et al., 2006).  In the present study, lovastatin 
elicited different effects on IBC proliferation as assessed by MTT assays (Figure 
3.25).  The MDA-IBC-3 cells were most sensitive to the drug, whereas SUM149 
and SUM190 proliferation was unaffected.  Campbell et al. (Campbell et al., 
2006) found that hormone receptor and ErbB2 status may be indicators of 
responsiveness to statin treatment.  In a recent clinical trial in which breast 
cancer patients were treated with fluvastatin, there was significantly reduced 
proliferation and increased apoptosis in tumors that were high grade as 
compared to low grade tumors (Garwood et al., 2010).   
Cysteine cathepsins, including cathepsin B, play a potentially significant 
role in development and progression of many cardiovascular diseases [for 
review, see (Lutgens et al., 2007)].  In a murine model of atherosclerosis 
increased cathepsin B message and protein levels are associated with highly 
inflammatory lesions (Chen et al., 2002) and treatment with statins reduces 
cathepsin B expression and activity in these lesions (Kim et al., 2009).  These 
same effects of statins are not specific to cysteine cathepsins but also extend to 
other classes of proteases, including both serine proteases (Denoyelle et al., 
2001) and MMPs (Thunyakitpisal and Chaisuparat, 2004; Abisi et al., 2008).  In 
our cultures of IBC cells, lovastatin decreased cathepsin B expression and 
activity (Figures 3.26 and 3.27).  In addition, lovastatin treatment diminished both 
the protein level and activity of cathepsin B in both TS and TI fractions of 3D 
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cultures of IBC cells (Figures 3.32 and 3.33). These data indicate that lovastatin 
is capable of reducing the association of cathepsin B with membrane lipid 
microdomains.  These findings are particularly interesting because we confirmed 
a functional role for cell surface cathepsin B.  CA074, a cell impermeable and 
highly selective cathepsin B inhibitor, significantly reduced pericellular proteolysis 
and invasion by SUM149 cells (Figures 3.6 and 3.7).  In agreement with these 
findings, lovastatin treatment, which diminished pericellular cathepsin B, also 
significantly reduced type IV collagen degradation and invasion by IBC cells 
(Figures 3.35 and 3.38).  Others have also shown that lovastatin decreases 
migration and invasion of breast cancer cells (Silva et al., 2003; Kang et al., 
2009), in part due to reduced expression of both MMP-2 and -9 (Kang et al., 
2009).  Another statin drug, cerivastatin, inhibits proliferation and invasion of 
highly aggressive MDA-MB-231 breast cancer cells, concomitantly with reduced 
expression of uPA, MMP-9, uPAR and PAI-1 (Denoyelle et al., 2001; Denoyelle 
et al., 2003).  In our studies, treatment of SUM149 cells with lovastatin resulted in 
decreased uPA expression and secretion (Figure 3.28).  The observed reduction 
of type IV collagen degradation and invasion by SUM149 cells are a result of 
lovastatin-induced decreases in expression of proteases, including cathepsin B 
and uPA. 
EGFR expression is associated with more aggressive subtypes of breast 
cancer and increased expression is also higher in IBC than non-IBC patient 
tissues (Guerin et al., 1989).  Therapies targeting EGFR (including the use of 
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small molecules against its tyrosine kinase domain, e.g. gefitinib and erlotinib, or 
cetuximab, a chimeric monoclonal antibody) resulted in little benefit (Rimawi et 
al., 2010).  This has led to combination strategies to maximize the potential of 
drugs and improve patient outcome [for reviews, see (Fischgrabe and Wulfing, 
2008; Sanchez-Munoz et al., 2009)].  In comparison to normal cells, cancer cells 
are highly dependent on products of the mevalonic pathway and generally have 
increased HMG-CoA reductase activity; therefore statins have been proposed for 
use as cancer therapeutics (Wong et al., 2002; Chan et al., 2003).  In addition, 
mevalonate metabolites are also important for EGFR signaling and effects of 
statins on EGFR have been investigated.  Lovastatin treatment inhibits 
autophosphorylation of EGFR and downstream signaling events (Mantha et al., 
2005; Dimitroulakos et al., 2006); inhibits dimerization of EGFR, decreases both 
AKT phosphorylation and inactivation of RhoA (Zhao et al., 2010); and has also 
been shown to sensitize resistant cells to drug treatment (Park et al., 2010).  In 
the current study, we demonstrated that lovastatin treatment of IBC cells reduced 
the localization of EGFR to lipid microdomains, which could be rescued by MVA 
(Figure 3.39).  Irwin et al. have demonstrated that EGFR in lipid microdomains 
mediates tyrosine kinase resistance and that treatment with lovastatin causes 
decreased Akt phosphorylation in SUM149 cells (Irwin et al., 2011).   Whether 
inhibition of downstream signaling is due to disrupted EGFR localization to lipid 
microdomains by lovastatin warrants further investigation. 
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 Stromal components of the IBC tumor microenvironment were not a focus 
of the current study.  However, previous findings by our laboratory have 
suggested that secreted factors from the conditioned media of human monocytes 
increase both expression and activity of cathepsin B in SUM149 cells (Mohamed 
et al., 2008).  Monocytes recruited from the circulation into the tumor 
microenvironment differentiate into tumor-associated macrophages.  The tumor-
associated macrophges secrete angiogenic factors and thereby promote tumor 
growth and invasion and are associated with poor prognosis in invasive breast 
cancer (Leek et al., 1996).  In addition, both tumor cell and macrophage 
associated cathepsin B promotes progression and metastatic spread in a murine 
model of mammary carcinogenesis (Vasiljeva et al., 2006).  Therefore, cathepsin 
B is expressed by tumor cells and many other tumor-associated cells, including 
macrophages, fibroblasts, endothelial cells, neutrophils and osteoclasts which 
contribute to neoplastic progression [for review, see (Mohamed and Sloane, 
2006)].  Therefore, statins, by decreasing both expression and activity of 
cathepsin B, may prove efficacious in treatment of malignancies associated with 
its overexpression and increased activity, such as IBC.  Combinational 
therapeutic approaches targeting both cathepsin B and uPAR have been shown 
by Rao and colleagues to inhibit tumor progression (Gopinath et al., 2010) and 
neovascularization in malignant glioma (Malla et al., 2011).  Several protease 
targeted drugs are routinely used in the clinic, e.g., ACE inhibitors, and others 
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are in pre-clinical development, including neutralizing antibodies against both 
cathepsin B and uPA for cancer treatment (for review, see (Turk, 2006)). 
This study was undertaken to investigate factors, in particular proteolytic 
networks, which mediate the aggressive IBC phenotype.  My overall hypothesis 
was that cell surface association of the cysteine protease cathepsin B, serine 
proteases of the plasminogen cascade and their binding partners in caveolae 
enhance cell surface proteolysis, and ultimately, the aggressiveness of IBC cells. 
We have demonstrated that there is active cathepsin B at the surface of IBC 
cells.  Targeting caveolae, a specialized lipid raft, by knockdown of caveolin-1 
expression in IBC cells reduces their ability to degrade ECM proteins and their 
invasiveness.  These studies confirm that caveolin-1 and caveolae play a critical 
role in the aggressive phenotype of IBC.  In IBC cells that express caveolin-1, 
proteases and signaling proteins are associated with caveolae, including uPA 
and EGFR.  Our studies therefore provide a mechanism for the role of caveolae, 
i.e., association of proteolytic pathways with caveolae in IBC cells and 
specifically the association of uPA and uPAR, components of the plasminogen 
activation system.  We have also demonstrated that targeting lipid rafts by 
treating IBC cells with lovastatin alters their aggressive phenotype.  In IBC cells 
that do not express caveolin-1, we showed that proteases are also associated 
with lipid rafts in the plasma membrane.  Those proteases include uPA and 
cathepsin B, an upstream activator of pro-uPA.  We also confirmed the presence 
of EGFR pathways in lipid rafts of IBC cells.  Thus, our studies demonstrate a 
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critical role for lipid rafts, both caveolar and non-caveolar, in the aggressive 
phenotype of IBC.  
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Inflammatory breast cancer (IBC) is an aggressive, metastatic and highly 
angiogenic form of locally advanced breast cancer.  Breast cancer invasion has 
been linked to proteolytic activity at the tumor cell surface. We observed that 
uPA, uPAR and enzymatically active cathepsin B were all present in caveolae 
fractions isolated from SUM149 cells.  Using a live-cell proteolysis assay, we 
demonstrated that both IBC cell lines degrade type IV collagen.  The SUM149 
cells exhibit predominantly pericellular proteolysis, consistent with localization of 
constituents of a proteolytic pathway to membrane microdomains.  A functional 
role for cathepsin B was confirmed by the ability of CA074, a cell impermeable 
and highly selective cathepsin B inhibitor, to significantly reduce pericellular 
proteolysis and invasion by SUM149 cells.  A statistically significant co-
expression of cathepsin B and caveolin-1 was found in IBC patient biopsies, thus 
validating our in vitro data.  To determine whether the uPA and cathepsin B 
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present at the cell surface is localized specifically to caveolae and investigate if 
caveolae are a functional component of the IBC phenotype, we knocked down 
the expression of caveolin-1 in SUM149 cells.  The subcellular distribution of 
cathepsin B was unchanged in caveolin-1 knockdown SUM149 cells.  In contrast, 
knockdown decreased the association of both uPA and EGFR with caveolae.   
Knockdown of caveolin-1 also decreased degradation of type IV collagen and 
invasion by IBC cells.  We also determined that targeted disruption of lipid 
microdomains by use of lovastatin diminished the aggressiveness of IBC cells.  
Cathepsin B activity and association with lipid microdomains was reduced in 
lovastatin treated IBC cells.  Lovastatin treatment also reduced type IV collagen 
degradation and invasion by IBC cells.  In conclusion, we have shown that 
cathepsin B and caveolin-1 both contribute to the aggressiveness of IBC, albeit 
by different mechanisms. 
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